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Data are presented on the drugs ordered,
prescribed, or administered by office-based
physicians to treat patients with principal
diagnoses that were among those most
commonly rendered during 1980. Diabetes
mellitus, hypertension, ischemic heart
disease, and certain respiratory conditions
are among the 15 illness-related diagnoses
selected. Drugs associated with visits for
three preventive care health services are
also included. For each diagnosis, percents
of visits in which one or more drugs were
provided, drug mention rates, and drug
intensity rates are reported by age, sex, and
race of the patient; problem status; and
major reason for visit. Drug mentions for
each diagnosis are also shown by therapeutic
category, physician’s entry mode, and
generic class.
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Office Visits for Selected
Diagnoses
by Beulah K. Cypress, Ph. D., Division of Health Care Statistics
Introduction Table A. Number and percent distribution of ofFice visits and drug mentions
by principal diagnosis United States, 1980
Purpose and background Principal diagnosis and ICD-9-CA4 codel
Office Drug
visits mentions
The purpose of this report is to provide information
about medication therapy in office visits for the 18
selected principal (first-listed) diagnoses shown in table A.
Diagnostic codes and groupings are based on the l’nter-
national Classij7cation of Diseases, 9th Revision,
Clinical Modification. 1 The data were collected in
1980 by the National Center for Health Statistics by
means of the National Ambulatory Medical Care Sur-
vey, a probability sample survey conducted annually by
the Division of Health Care Statistics.
Two brief reports on medication therapy in the
National Ambulatory Medical Care Survey have been
published. They highlighted the drugs most frequently
used in oi%ce-based practice, and drug utilization by sex
and age of the patient.z,s This report explores the statis-
tical association between certain diagnoses and the
pharmacologic treatment modality, a fimdamental med-
ical relationship. A brief report on medication therapy
in visits for hypertension has also been published.A The
conditions and health services shown in table A were
selected because they were among the most common
diagnoses rendered during office visits in 1980. They
accounted for 38 percent of all visits and 45 percent of
all drug mentions. Data on the general characteristics
and dimensions of drug therapy during visits for care
and treatment of these diagnoses are presented in sec-
tion I. The drug parameters used in the National Ambu-
latory Medical Care Sumey include entry status (brand
namea or generic entity), prescription status (prescrip-
tion or over-the-counter drug), composition status (single
ingredient or combination drug), and Federal control
status (drugs under the regulatory control of the Drug
aInclusion of brand or trade names is for identification only end does not
imply endorsement by the Public Health Service or the U.S. Department of
Health and Human Services.
All principal diagnoses . . . . . . . . . . . . . . . . . . . . . . .
Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . 250
Obesity and other hyperalimentation. . . . . ...278
Neurotic disorders or depressive disorder,
NEC2 . . . . . . . . . . . . . . . . . . . . . . . . . . .300, 311
Suppurative and unspecified otitis media . ...382
Essential hypertension . . . . . . . . . . . . . . . . ...401
Ischemic heart disease. . . . . . . . . . . . ...410-414
Acute upper respirato~ infections of multiple or
unpacified sites (acute URI). . ..460. 461,465
Acute pharyngitis or acute laryngitis and
tracheitis . . . . . . . . . . . . . . . . . . . . . ...462.464
Allergic rhinitis . . . . . . . . . . . . . . . . . . . . . . . ...477
8ronchitis, acute; or not specified as acute
or chronic . . . . . . . . . . . . . . . . . . . . ...466.490
Asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...493
Diseases of sebaceous glands . . . . . . . . . . ...706
Osteoarthritis and allied disorders or other
and unspecified arthropathies. . . . ...715-716
Intervertebral disc disorders or other and
unspecified disorders of back . . . . ...722. 724
Sprains and strains of sacroiliac region or other
and unspecified parts of back . . . . ...846-847
Health supervision of infant or child . . . . . . . . V20
Normal pregnancy . . . . . . . . . . . . . . . . . . . . . ..V22
General medical examination . . . . . . . . . . . . . . V70
























‘1~a~ed on the ,nternations[ classification of Diseases, 9th Revision, Clinical MOdifics-
rion. See reference 1.
2NEC = not elsewhere classified.
Enforcement Agency of the U.S. Department ofJustice).
Sections II through VII describe drug utilization relative
to visits for speciilc diagnoses in terms of sex, age, and
race of the patien$ problem status; and major reason for
visit. In these sections drugs that were ordered or pro-
vided in the presence of these diagnoses are also cate-
gorized by therapeutic effect and listed by specific drug
1
names as well as generic substances. Therapeutic cate-
gories are based on the American Hospital Formulary
Service classification systems In the National Ambu-
latory Medical Care Survey drug file each drug entry
was assigned to one American Hospital Formulary
Service therapeutic category although for some drugs
more than one therapeutic effect is possible. In order to
report accurately what the physician prescribed, drug
mentions used in this report are based on the physicians’
entries on the Patient Record Form (see appendix III).
These entries may be brand or generic names of pre-
scription or over-the-counter drugs, or a therapeutic
effect. “Drug mentions” include all new or continued
drugs listed in item 11, parts a and b, on the Patient
Record Form. Part 11b, it should be noted, may relate
to diagnoses other than the principal or first-listed diag-
nosis. Therefore, it is assumed that medications de-
scribed in this report were ordered for patients with the
first-listed diagnosis but may not necessarily be thera-
peutic agents for that condition. The terms “medica-
tion” and “chug” are used interchangeably in this report.
The “prescriber” is assumed to be the reporting physi-
cian. While the verb “prescribe” usually indicates a
written formula or drug name to be dispensed by a
registered pharmacist, in the context of this report it is
used interchangeably with “ordered” or “provided.”
Therefore, it may also mean a recommendation by the
physician for an over-the-counter drug, or the admin-
istration of a substance during the visit.
The methodology used to collect and process this
drug information is described in Vital and Health Sta-
tistics, Series 2, No. 90.6 A detailed description of the
survey methodology was published in Vital and Health
Statistics, Series 2, No. 61.7 To assist the reader in
interpreting the statistics in this report, the scope of the
survey and the source and limitations of the data are
described briefly prior to data presentation. Detailed
technical notes, definitions of terms, and facsimiles of
survey instruments are presented in appendixes I–III.
Scope of the survey
The basic sampling unit for the National Ambu-
latory Medical Care Survey is the physician-patient en-
counter or visit. Within the current scope of NAMCS
are all office visits made in the conterminous United
States by ambulatory patients to nonfederally employed
ofi-lce-based physicians as classified by the American
Medical Association or the American Osteopathic As-
sociation. The National Ambulatory Medical Care
Survey physician universe excludes physicians practic-
ing in Alaska and Hawaii and physicians in the special-
ties of anesthesiology, pathology, or radiology. Visits to
physicians principally engaged in teaching, research, or
administration, as well as telephone contacts and visits
made outside the physician’s ofilce, are excluded.
The definitions of office, physician, patient, and
visit in terms of eligibility for the National Ambulatory
Medical Care Survey are presented in appendix II.
Source and limitations of data
Estimates presented here are based on information
obtained through the completion of Patient Record
Forms (appendix III) for a sample of visits to a national
probability sample of office-based physicians. The
sample for the 1980 National Ambulatory Medical
Care Survey (NAMCS) included 2,959 physicians, of
whom 611 were found not eligible (out of scope) at the
time of the survey. Of the 2,348 physicians who were
eligible for participation in NAMCS, 1,869 (79.6 per-
cent) actually participated in the survey (see appendix
T\
~).
Physicians who participated in the survey main-
tained a list of all office visits during a randomly assigned
7-day reporting period. For a systematic random sample
of these visits, information was recorded on the Patient
Record provided for that purpose. During 1980, re-
sponding physicians completed 46,081 Patient Record
Forms on which they recorded 51,372 drug mentions.
The appendixes to this report contain information
that is necessary for a proper understanding and inter-
pretation of the statistics presented. Appendix I con-
tains a general description of the survey methods, the
sample design, and the data collection and processing
procedures. Methods of estimation and imputation are
also presented. Because the statistics given here are
based on a sample of office visits rather than on all visits,
they are subject to sampling errors. Therefore, particular
attention should be paid to the section entitled “Relia-
bility of estimates.” Charts on relative standard errors
and instructions for their use are also given in appendix I.
Definitions of terms used in this report and in the
survey operations are presented in appendix II. A fac-
simile of the Patient Record Form is reproduced in
appendix 111.Facsimiles of other survey materials such
as the introductory letter and Induction Interview Form





Office visits and drug mentions
A study of medication therapy by diagnosis begins
with the number of ofllce visits, number and percent of
visits in which one or more drugs were ordered or pro-
vided (drug visits), and number of drug mentions. These
basic data are shown in table 1. Two rates are also
provided. The drug mention rate is the number of drug
mentions divided by the number of all visits for a given
diagnosis. The drug intensity rate is the number of drug
mentions divided by the number of drug visits for a given
diagnosis.
On the average, medication therapy was used in 63
percent of all office visits in 1980, but this percent
varied greatly for various diagnoses. For the 18 diag-
noses in this report, proportions of drug visits ranged
from a low of 29 percent for general medical examina-
tion to a high of 94 percent for certain respiratory con-
ditions. Illness-related diagnoses in this group were
more likely to be associated with drug therapy than were
visits for preventive care. The highest drug mention rate
was for ischemic heart disease (2.54); the two lowest
were for general medical examination and normal preg-
nancy (0.41 each). The lowest illness-related drug men-
tion rate (0.88) was for neurotic disorders or depressive
disorder, NEC (NEC = not elsewhere classified); fol-
lowed by two musculoskeletal conditions; sprains and
strains of sacroiliac region or other and unspecified
parts of back (0.89) and intervertebral disc disorders
or other and unspecified disorders of back (1.18).
The variation in rates among diagnoses is illustrated in
figure 1.
Visits for some diagnoses were more drug intensive
than others. Therefore, rates representing the number of
drugs per drug visit may not vary indirect proportion to
drug mention rates. For example, the drug intensity rate
of 1.67 for neurotic disorders or depressive disorder,
NEC, was not the lowest illness-related drug intensity
rate, but averaging over all visits for this diagnosis drug
utilization was lower than it was for other conditions in
this report. Allergic rhinitis was less drug intensive than
neurotic disorders or depressive disorder, NEC, with a
drug intensity rate of 1.38. This underscores the inter-
pretive distinction between the two rates. When drugs
were used for allergic rhinitis patients, the average
number per drug visit was 1.38; when the patient had a
neurotic disorder or depressive disorder, NEC, the aver-
age number per drug visit was 1.67, even though 52
percent of such visits included drugs compared with 90
percent of those for allergic rhinitis.
Number of medications
The proportions of visits according to the precise
number of medications for each listed diagnosis is shown
in table 2. The proportions shown in the “None” cate-
gory are the complements of the percent of drug visits
shown in table 1. Proportions of drug visits according to
number of medications maybe calculated by omitting
this group. For example, 20.9 percent of all visits with
general medical examination, or 3,360,000, had one
drug entry. Dividing this number by total drug visits
shown in table 1 (4,732,000) yields an estimate of71
percent of drug visits with one medication. Visits were
more likely to fall in the “None” group when patients
visited for the preventive care services described in this
repo~, neurotic disorders or depressive disorder, NEC;
sprains and strains of sacroiliac region or other and
unspecfled parts of back; and intervertebral disc dis-
orders or other and unspecified disorders of back. One
medication was the most common number in visits for
other diagnoses in table 2 except for ischemic heart
disease; acute upper respiratory infections of multiple
or unspecified sites (acute URI); bronchitis, acute; or
not specified as acute or chronic; and diseases of se-
baceous glands, where two was the likely number of
drug mentions. Close to half (49 percent) of the visits for
ischemic heart disease were in the total of categories
three, four, or five or more drugs. Other diagnoses with a
relatively high total proportion of three, four, or five or
more drugs were diabetes mellitus (27 percent); obesity
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Diabetea mellitua
Obesity and other hyperalimentation
Neurotic disorders or depressive
disorder, NEC1




Acute upper respiratory infections of
multiple or unspecified sites
(acute URI)
Acute pharyngitis or acute laryngitis
snd tracheitis
Allergic rhinitis
Bronchitis, acute; or not specified ss
scute or chronic
Asthma
Diseases of sebaceous glsnds
Osteoarthritis and allied disorders or
other and unspecified arthropathies
intervertebral disc disorders or other
and unspecified disorders of back
Sprains and atrains of sacroiliac region
or other and unspecified parts of back
Health supervision of infant or child
Normal pregnancy
General medical examination
1NEC = not elsewhere classified,
Figure 1. Drug mention rates per visit for selected diagnosea: United States, 1980
and other hyperalimentation (36 percent); essential hy- The association between the number of medications
pertension (26 percent); asthma(31 percent); diseases ordered or provided in the presence of selected diag-
of sebaceous glands(32 percent); and osteoarthritis and noses and other variables, such as sex and age of the
allied disorders or other and unspecified arthropathies patient, is detailed in the remaining sections of this
(26 percent). report.
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Entry status Composition status
On the average, 7 of 10 drug entries on the Patient
Record Form were identiiled by brand name (manu-
facturer’s product name). A convention adopted for this
report is that an entry name is spelled with an initial
capital letter. A higher than average use of brand names
occurred when the diagnoses were neurotic disorders or
depressive disorder, NEC (85 percent); intervertebral
disc disorders or other and unspecified disorders ofback
(85 percent); and sprains and strains of sacroiliac region
or other and unspecified parts of back (83 percent)
(table 3). Although proportions of brand name entries
exceeded genericb name entries, a higher than average
use of generic names was found with diabetes mellitus
(33 percent), obesity and other hyperalimentation (35
percent), acute pharyngitis or acute laryngitis and
tracheitis (34 percent), health supervision of infant or
child (75 percent), and general medical examination
(45 percent). The relatively high proportions of generic
entities mentioned with the last two diagnoses were
probably due to the large number of immunizations
given during their total visits. This is discussed in more
detail in section VII. Similarly, the proportions of entries
described by therapeutic effect when visits were for
allergic rhinitis (42 percent) and asthma (13 percent)
reflect the use of drugs, allergens, or other desensitizing
agents administered by injection without specific iden-
tification of the pharmaceutical agent. Drug therapy for
these two diagnoses is discussed in section V.
Prescription status
Brand name drugs may be prescription (a written
order from the physician to be filled by a registered
pharmacist) or nonprescription, also called “over the
counter. ” Drugs identified by the physician by generic
name usually require a prescription with some excep-
tions, notably aspirin and insulin. Eighty-three percent
of all drug mentions, regardless of diagnosis, were pre-
scription drugs and 13 percent were over-the-counter
drugs (table 3). The higher than average proportion of
over-the-counter drugs mentioned in visits for diabetes
mellitus (25 percent) was due to the utilization of insulin
(other anti-diabetic agents are prescription drugs). Over-
the-counter drugs were also more frequently mentioned
when acute URI (17 percent) and acute pharyngitis or
acute laryngitis and tracheitis (15 percent) were diag-
nosed, probably due to the availability of many over-
the-counter drugs used for symptomatic relief of these
conditions. Another condition with a high proportion of
over-the-counter drugs, in this case due to vitamin men-
tions, was normal pregnancy. Specific drugs mentioned
with these diagnoses are discussed in subsequent sec-
tions of this report.
bFor some dregs the brand nae used by the manufacturer to market the
product is in fact the generic class of the substance. In NAMCS such drugs
were classified in the generic name category.
Composition status describes the drug entry accord-
ing to whether it is a single ingredient drug, a combina-
tion drug, or a multivitamin. Single ingredient drugs
include all drugs with one active ingredient. Combina-
tion drugs consist of more than one active, principal
ingredient. On the average, 7 of 10 drugs mentioned
were single ingredient drugs (table 4). This number was
higher when the diagnoses were diabetes mellitus (85
percent); obesity and other hyperalimentation (83 per-
cent); neurotic disorders or depressive disorder, NEC
(80 percent); essential hypertension (73 percent);
ischemic heart disease (88 percent); acute pharyngitis
or acute laryngitis and tracheitis (74 percent); and dis-
eases of sebaceous glands (78 percent). Although for all
diagnoses, except normal pregnancy, single ingredient
drugs were more likely to be ordered than combination
drugs, higher than average proportions of combination
drugs were associated with suppurative and unspecified
otitis media (40 percent); acute URI (37 percent); bron-
chitis, acute; or not specified as acute or chronic (31
percent); sprains and strains of sacroiliac region or
other and unspecified parts of back (38 percent); and
health supervision of infant or child (37 percent). In
children’s health supervision visits the relatively large
proportion of mentions of combined vaccines (such as
diphtheria and tetanus toxoids and pertussis vaccine)
contributed to the total of combination drugs (see sec-
tion VII). Multivitamins were prominent in visits for
normal pregnancy (60 percent).
If the physician entered a therapeutic effect rather
than a drug name, it was not possible to make certain
categorizations (this applies also to prescription status).
Proportions in the “undetermined” category with visits
for allergic rhmitis (44 percent) and asthma (15 per-
cent) were due to the large number of entries marked
“allergy relief” with no further identification of the
pharmaceutical agents used (see section V).
Federal control status
Regulatory control of certain drugs rests, by law, in
the Drug Enforcement Agency of the U.S. Department
of Justice, which has assigned each regulated drug to
one of five categories. These classiilcations constitute a
scale based on two dimensions: potential for abuse,
ranging from high (I) to low (V); and psychological or
physical dependence, severe (I) to limited(V). All regu-
lated drugs except those in schedule I have a currently
accepted medical use in the United States. Classifica-
tions and examples are as follows:
. Schedule I (Heroin, LSD, Marijuana). High poten-
tial for abuse. Lack of accepted safety for use under
medical supervision.
● Schedule II (Methaqualone, Meperidine, Ampheta-
mines). High potential for abuse. Abuse may lead to
severe psychological or physical dependence.
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● Schedule HI (Paregoric, Fiorinal, Phendimetra-
zine). Potential for abuse less than for drugs in
schedule II. Abuse may lead to moderate or low
physical dependence or high psychological depend-
ence.
. Schedule IV (Diazepam, Flurazepam, Phenter-
mine). Potential for abuse less than for drugs in
schedule III. Abuse may lead to limited physical or
psychological dependence.
● Schedule V (Lomotil, Cheracol Syrup). Potential
for abuse and dependence less than for drugs in
schedule IV.
About 87 percent of drugs mentioned in NAMCS
were uncontrolled and about 9 percent were controlled
(table 4). Higher than average proportions of controlled
drugs were found in visits for five diagnoses: obesity and
other hyperalimentation (32 percent); neurotic disorders
or depressive disorder, NEC (33 percent); bronchitis,
acute; or not specified as acute or chronic ( 13 percent);
intervertebral disc disorders or other and unspecit3ed
disorders of back (25 percent); and sprains and strains
of sacroiliac region or other and unspecitled parts of
back (26 percent). Controlled drugs used with these
diagnoses are detailed by schedule in the sections of this
report that deal with the individual diagnoses.
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Table 1. Number of office visits, number and percent of drug visits, number of drug mentions, drug mention rate, and drug intensity rate,
by all diagnoaes and selected principal diagnoses United States, 1980













thousands Rate per visit
All diagnoses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 250
Obesity andother hyperalimentation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 278
Neurotic disorders or depressive disorder, NEC4 . . . . . . . . . . . . . . . . ...300. 311
Suppurative andunspecified otitis media . . . . . . . . . . . . . . . . . . . . . . . . . . ...382
Essential hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...401
Ischemic haart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .410-414
Acute upper respiratory infections of multiple or unspecified sitea (acute
LJRI). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...460.461.465
Acute pharyngitis or acute laryngitis and tracheitis . . . . . . . . . . . . . . ...462. 464
Allergic rhinitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...477
8ronchitis, acut~ or not specified as acute or chronic . . . . . . . . . . . ...466. 490
Asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...493
Oiseasea ofsebaceous glands... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...706
Osteoarthritis andallied disorders orotherand unspecified arthropathies. . ..715-716
Intervertebral disc disorders orotherand unspecified disorders of back. .. 722,724
Sprains and straine of sacroiliac region or other and unspecified parta of
back . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...846-847
Health supewision ofinfant orchild . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..V20
Normal pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .V22



















































































































1~a~ed on the /nternatjonaI C\a~sjfjc8t/onof D;seases, 9th Revision, Clinical Modification. See refarence 1.
2Drug mentions divided by number of visits.
3Drug ~e”tions divided by number Ofdmg visi~.
4NEC = not elsewhere classified.
Table 2. Number and percent distribution of office visita by number of medications, according to all diagnoaes and selected principal diagnose= United States, 1980
Number of medications
Principal diagnosis and ICD-9-CM code~ All visits





All diagnoses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...250
Obesity andother hyperelimentation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...278
Neurotic disorders or depressive disorder, NE& . . . . . . . . . . . . . . . . ...300.311
Suppurative andunspecified otitis media. . . . . . . . . . . . . . . . . . . . . . . . . . . ...382
Essential hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...401
Ischemic heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...410-414
Acute upper respirsto~ infections of multiple or unspecified sites (acute
URN). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...460.461.465
Acute pharyngitis or acute laryngitis and tracheitis . . . . . . . . . . . . . . ...462. 464
Allergic rhinitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...477
Bronchitis, acute; or not specified as acute or chronic. . . . . . . . . . . . ...466. 490
Asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...493
Diseases of sebaceous glands . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...706
Osteoarthritis andallied disorders orotharand unspecified arthropathies . ..715-716
lntewertebral disc disordera orotherand unspecified disorders of back. .. 722,724
Sprains and strains of sacroiliac region or other and unspecified pens of
back . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...846-847
Health supervision ofinfant orchild. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .V20
Normal pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .V22























































































































































1Basedon the jnternatjona\ Classifjcario” of Diseases, 9th Revision, Clinical Modification. See reference 1.
2NEC = not elsewhere classified.
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Table 3, Percent distribution of drug mentions by entry status and prescription status, according to all diagnoses and selected principal diagnosa= United States, 1980
Entry status Prescription status
Principal diagnosis and ICD-9-CA4 code~ Total
Brand Generic Therapeutic Prescription
Non-
Undetermined
name name effect drug
prescription Undetermined
drug
All diagnoses . . . . . . . . . . . . . . . .
Diabetes mellitus . . . . . . . . . . . . . . . . . .,250
Obesity and other hyperalimentation . ..278
Neurotic disorders or depressive disorder,
NEC4 . . . . . . . . . . . . . . . . . . . . . ..3OO. 311
Suppurative and unspecified otitis
media . . . . . . . . . . . . . . . . . . . . . . . . ...382
Essential hypertension. . . . . . . . . . . . ...401
Ischemic heart disease ., . . . . . . . . 410–414
Acute upper respiratory infections of
multiple or unspecified sites
(acute URl) . . . . . . . . . . . . ..460.461 .465
Acute pharyngitis or acute laryngitis and
tracheitis. . . . . . . . . . . . . . . . . . 462, 464
Allergic rhinitis . . . . . . . . . . . . . . . . . . ...477
Bronchitis, acute: or not specified as
acute or chronic . . . . . . . . . . . . . . 466,490
Asthma . . . . . . . . . . . . . . . . . . . . . . . . ...493
Diseases of sebaceous glands. . . . . . ...706
Osteoarthritis and allied disorders
or other and unspecified
arthropathies . . . . . . . . . . . . . . ..715–716
lntewertebral disc disorders or other and
unspecified disorders of back. .722, 724
Sprains and strains of sacroiliac region or
other and unspecified parts
of back . . . . . . . . . . . . . . . . . . . ..846-847
Health supewision of infant or child . . V20
Normal pregnancy . . . . . . . . . . . . . . . . ..V22




















































































































1 Based on the International Classification of Diseases, 9th Revision, Clinical Modification. See refarence 1.
2NEC = “Ot elsewhere classified
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Table 4. Percent distribution of drug mentions by composition status and Federal control status, according to all diagnoses and
selected principal diagnoaes United Ststes, 1980












All diagnoses . . . . . . . . . . . . . . . . . . . . . .
Diabetes mellitus . . . . . . . . . . . . . . . . 250
Obesity and other
hyperalimentation. . . . . . . . . . . . . 278
Neurotic disorders or depressive
disorder, NEC2 . . . . . . . . ...300.311
Suppurative and unspecified
otitis media . . . . . . . . . . . . . . . ...382
Essential hypertension . . . . . . . . ...401
Ischemic haart disease . . . ...410-414
Acute upper respiratory infections
of multiple or unspecified sites
(acute URI). ., . . . . ...460.461.465
Acute pharyngitis or acute laryngitis
and tracheitis . . . . . . . . . . . .462, 464
Allergic rhinitis . . . . . . . . . . . . . . . .. 477
8ronchitis, acute; or not specified
as acute or chronic. . . . . ...466. 490
Asthma . . . . . . . . . . . . . . . . . . . . . . . . 493
Diseases of sebaceous glands. . ...706
Osteoarthritis and allied disordera
or other and unspecified
arthropathies . . . . . . . . . . . . 715-716
intervertebral disc disorders or other
and unspecified disorders of
back . . . . . . . . . . . . . . . . . ...722.724
Sprains and strains of sacroiliac region
or other and unspecified parts
of back . . . . . . . . . . . . . . . . . 846-847
Health supervision of infant
or chid., . . . . . . . . . . . . . . . . . . ..VZO
Normal pregnancy. . . . . . . . . . . . . . . v22
























































































































*2.2 9.7 88.0 2.4














1Based on the lnternationa\ classification of Diseases, 9th Revision, Clinicsl Modification. see reference 1.
2NEC = not ~l$ewhere classified.
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Section II■ Selected endocrine
and metabolic disorders
Diabetes mellitus
Patients with diabetes mellitus made about 9.6 mil-
lion visits to office-based physicians in 1980 (table 5).
During these visits there were about 17.5 million men-
tions of drugs for an average of 1.83 drugs per visit. In
about 80 percent of all visits, one or more drugs were
utilized.
DiiTerences in drug rates between females and males
were not statistically significant. The drug mention rates
for members of the black and white races were identical.
However, the age of the patient was a significant factor
in drug utilization. Drug therapy was more likely to be
used in visits by patients 65 years of age and older (drug
mention rate = 2.18) than in those by patients 45 –64
years of age (1.71).
Rates were also higher when patients returned to the
same physician for continuing care (old problems) than
when they presented diabetes mellitus as anew problem.
Most visits for diabetes mellitus were characterized
by the physician as routine chronic problems (75 per-
cent). However, in the 8 percent of visits described as
chronic problem, flareup, the drug mention rate was
2.53 compared with 1.82 in routine visits.
When visits were grouped by exact number of medi-
cations, as shown in table 6, the highest proportion was
in the category of one drug regardless of the patient’s
sex, age, or race. However, the proportion of visits with
only one medication decreased as the patient’s age
group increased, while proportions of visits in the cate-
gories of three, and four or more increased.
Drug mentions are distributed by therapeutic cate-
gories in table 7. (The American Hospital Formulary
Service classification system is shown in appendix IV.)
About 83 percent of drugs used were in four categories:
cardiovascular drugs; central nervous system drugs;
electrolytic, caloric, and water balance; and hormones
and synthetic substitutes. The last category constituted
the highest proportion (40 percent), followed by cardio-
vascular drugs with 19 percent. Drug mention rates,
which are also shown in table 7, indicate that hormones
and cardiovascular drugs were ordered proportionately
more frequently for patients 65 years of age and older
than for those in younger age groups.
The specific drugs entered most frequently on Pa-
tient Record Forms when diabetes mellitus was the
principal diagnosis are shown in table 8. Each entry is
described in this table by its principal generic ingred-
ients and therapeutic category. Drug names are based
on the physicians’ entries and may be brand or generic
names. If only one generic ingredient is listed,, it maybe
because the physician ordered the drug by its generic
name or because the physician’s entry was a brand
name of a single ingredient drug. Not all ingredients are
listed for every combination drug. The NAMCS drug
file lists up to five active ingredients.
It is apparent that the hormones and synthetic sub-
stitutes group consisted chiefly of insulin, which had 3.2
million mentions. Diabinese ( 1.7 million), Orinase (0.8
million), and Tolinase (0.6 million) were also frequently
mentioned. Among cardiovascular drugs prescribed
during visits by diabetic patients, Aldomet (a.hypoten-
sive agent), Lanoxin, and Digoxin (two cardiac drugs)
were predominant. Lasix and Dyazide were the leading
diuretics prescribed. These nine drugs, representing
three therapeutic categories, accounted for about 49
percent of all drug mentions with diabetes mellitus as
the principal diagnosis. The inclusion of hypotensive
agents, diuretics, and cardiac drugs in this list of drug
mentions reflects the two conditions frequently con-
comitant when diabetic patients visi~ hypertension and
ischemic heart disease.g According to NAMCS data,
an anti-diabetic agent without mention of a diuretic,
hypotensive agent, or cardiac drug was ordered in 46
percent of all drug visits (although other drugs may have
been mentioned). An anti-diabetic agent with a diuretic
but not a hypotensive agent or a cardiac drug was pre-
scribed in 13 percent, an anti-diabetic agent with a
hypotensive agent but not the other two in 6 percent, and
an anti-diabetic agent with a cardiac drug alone in 5
percent. About 6 percent of visits included all four
drugs. Patients 25–44 years of age were more likely to
be treated with an anti-diabetic agent without one of the
other three types of drugs (72 percent) than were those
10
aged 45–64 years (47 percent) or 65 years of age and
older (37 percent).
Exogenous insulin accounted for 18 percent of all
drug mentions. Diabinese, Orinase, and Tolinase, which
are oral hypoglycemic, also accounted for 18 percent
of the total. The 6.3 million mentions of these four anti-
diabetic agents are distributed by route of administra-
tion and sex and age of the patient in table B. There were
no statistically signilcant differences by sex, but age
was a factor in the choice of drug therapy. Proportions
of oral hypoglycemic increased and those of insulin
decreased as the patient’s age group increased.
. Because in NAMCS the primary identification of a
drug was based on the physician’s entry, the specific
drugs in table 8 were listed by brand or generic name,
whichever the physician wrote and which may well have
been the same pharmaceutical agent. For example,
Lanoxin is a brand name and digoxin is a generic name,
but both are the same substance. Therefore, it is also
important to know the quantity of speciiic generic sub-
stances prescribed as single ingredients or extant in
combination with other substances. The most frequently
used generic substances in visits for diabetes mellitus
are listed alphabetically by form of use in table 9. It
should be noted that it is not possible to sum the number
of uses of generic substances and arrive at a total of 100
percent of drug mentions because many generic sub-
stances are found in combination with other drugs, thus
creating a duplicated count of mentions. In addition,
quantities in table 9 may not agree with those in table 8.
One reason for this discrepancy is that a single ingre-
dient generic entity may be marketed under different
brand names. The totals in table 9 include all mentions
where the generic entity was an ingredient, whereas
table 8 shows only the most frequent entries. As may be
expected, the most frequent generic substance used was
insulin. It was followed by chlorproparnide (represented
in table 8 by Diabinese) and hydrochlorothiazide.
Control of food intake is important in the manage-
Table B. Number and percent distribution of selected anti-diabetic agents
mentioned in office visita for diabetea mellitus by route of administration
of the drug, according to sax and age of the patient United Statea, 1980
Number of
selected




Female . . . . . . . . . . . . . . . . 3,740 100.0 51.2 48.8
Male . . . . . . . . . . . . . . . . . . 2,593 100.0 47.2 52.8
Age
25-44 yeara . . . . . . . . . . . . 716 100.0 21.9 78.1
45-64 yeara . . . . . . . . . . . . 2,476 100.0 48.8 51.2
65yeara and over . . . . . . . 2,873 100.0 60.5 39.5
1~abine~e (chl~~r~pamide], Orinase (tolbutamide), and Tolinase (tolazamide).
‘Insulin.
ment of diabetes mellitus, whether or not the patient
requires medication therapy. Diet counseling was in-
cluded in 38 percent of visits by patients with diabetes
mellitus. Patients were more likely to be instructed
about diet when they were on medication, however,
than when drugs were not indicated during the visit.
About 42 percent of visits with medication therapy
included diet counseling compared with 26 percent of
visits without medication.
Obesity and other hyperalimentation
Basic data on office visits and drug mentions are
shown in table 10. There were about 8.1 million visits
for obesity and other hyperalimentation, yielding a drug
mention rate of 1.86. Most visits (83 percent) were
made by women, and their drug mention rate of 1.97
was significantly higher than that of men (1.37). This
was mainly because 85 percent of visits by women in-
cluded one or more drugs compared with only 65 percent
of those by men. The widest gap in rates by sex of the
patient was associated with this diagnosis. The drug
mention rates by sex of the patient for obesity and for six
other diagnoses are illustrated in figure 2. Of those
plotted, differences in rates for two diagnoses were not
statistically signiilcan~ ischemic heart disease and neu-
rotic disorders or depressive disorder, NEC (NEC =
not elsewhere classified).
Patients 25 years of age and over made 89 percent
of the visits and they were more likely to be given
medication therapy than were patients less than 25
years of age.
More than twice as many visits were made by pa-
tients returning for care of the same problem than by
those presenting new problems, but the drug rates were
higher for new problem visits. The drug mention rate for
new problems was 2.27 compared with 1.70 for old
problems. The same comparison for the drug intensity
rate was 2.77 and 2.09. These rates suggest an inverse
relationship between the number of drugs and visit status.
Of all new problem visits, 41 percent included three
drugs compared with 12 percent of old problem visits
with the same number. One drug was ordered in only 11
percent of new problem visits compared with 37 percent
of return visits (table 11).
Drugs utilized for obesity patients were chiefly in
three groups: central nervous system drugs, diuretics,
and hormones and synthetic substitutes (table 12). These
therapeutic categories constituted 81 percent of all drug
mentions, with central nervous system drugs account-
ing for 39 percent. The drug mention rate of 76 central
nervous system drugs per 100 visits for women was
higher than that for men (56). Patients 25–44 years old
were also more likely to be given central nervous system
drugs than were older patients.
Chorionic gonadotropin, a member of the hormones
and synthetic substitutes group, accounted for 10 per-
cent of all mentions and, based on entry names, was the
11
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%:.:.%:. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .:.:.:%... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Female. .. .. . .. .. .. . .. .. .. . .. .. . . .. . .. .. .. . .. .. .. . .. . . .. . .. .. .. . .. .. .. .. . .. .. .. . . ●.*.* .
❑
%%..+
. .. . .. .. . . Male
:.:.:.:.:
Eaaential hypertension
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Iachemic heart diaeaae
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Neurotic disorders or depressive disorder,
NEC1 . . . . . . . . . . . .
... . .. .. . . .. . .. . . .. . .. . . ..
... .. . .. .. .. . .. . . .. . .. .. ... . . . . . . . . . . . .
Bronchitis, acute; or not specified as
acute or chronic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . ... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Allergic rhinitis
:.:.:.:.:.:.:. :.:.:.:.:.:.:.:.:.:.:.:.:.:.:.~.~
.. .. .. . .. . . .. . .. .. .. .. . .. . . .. . .. .. .. .. . .. .. .. . .. . . .
.:.:.:.:.:.:.:.:.:.:.:.:.:.:.~.~.~.%
Intervertebral disc disordera or other and
unspecified disorders of back . . . . . . . . . . . . . . . . . . . . . ... . . .. . .. .. .. . .. .. . . .. . .. . . .. . .. . . .. . .. .. .. .. . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . .
.. . . .. .. . .. .. .. . .. .. .. . .. . . .. . .. . . .. . .. . . .. .. . . . . . . . . . . . . . . . . . . . . .
w ‘ I I 1 I I I I I I I I
o 0.6 0.6 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8
1NEC = not elsewhere classified. Drug mention rate per viait
Figure 2. Drug mention rates per visit for selected diagnoses by sex of patient United States, 1980
most frequently mentioned drug (table 13). This drug is (4.8 million) in visits for obesity were under the regu-
latory control of the Drug Enforcement Administration.
This group of mentions is distributed by Drug Enforce-
ment Administration schedule in table C. About 20
usually a-dministered by intramuscular injection. It was
reported in the 1981 Physicians’ Desk Reference that
this hormone has not been demonstrated to be effective
in attaining weight loss or appetite control.g The Amer-
ican Drug Index, 1981 does not list obesity among the
uses described for this drug. 10
Two diuretics, Lasix and Hydrochlorothiazide, were
also among the most frequent specific drugs prescribed
for obesity patients (13 percent of mentions). Three
anorexients with brand names Ionamin, Fastin, and
Phentermine (all in the generic class phentermine) ac-
counted for another 13 percent. Three of every four drug
visits included at least one drug that was a hormone or
an anorexient.
As shown in table 14, phentermine was the leading
generic substance used for treatment of obesity. When
entry names were listed in table 13, chorionic gonado-
tropin was the most frequent, but three separate brand
names for phentermine were listed. Thus, phentermine
was the leading generic substance used.
Table 4 showed that 32 percent of the drug mentions
Table C. Number and percent distribution of federally controlled drug
mentions in office visits for obesity and other hyperalimentation by con-





Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,804
Percent distribution
Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100.0
Schedule I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.0
Schedule I l . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19.9
Schedule ill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13.2
Schedule IV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66.4
Schedule V . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.5
1Based on the classification system of the Drug Enforcement Agency of the Depatiment of
Justice.
12
percent of the regulated drugs were in schedule II; 13 schedule ~ phendimetrazine, schedule ~, phentermine
percent in schedule 1~, and 66 percent, the largest and diethylpropion, schedule IV. There may have been
group, in schedule IV. (See section I for a description of
the schedules and the scale.) Among the drugs listed in
other regulated substances used in obesity visits, but
their numbers did not meet National Center for Health
table 14, four are controlled. Dextroamphetamine is in Statistics standards of reliability for reporting.
Table 5. Number of office visits for diabates mellitus, number and percent of drug vieite, number of drug mentions, drug mention rate, and drug intensity rate,







All visits Drug visitsl rate2 rate3
Number in Number in Number in
Sax thousands thousands Percent thousands Rate per visit
Both sexes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49,551 7,592 79.5 17,496 1.83 2.30
Female, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,683 4,544 80.0 11,100
Male . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.95 2.44
3,868 3,048 78.8 6,396 1.65 2.10
Age
Under 45 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,473 1,019 69.2 1,817
45-64 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.23 1.78
4,108 3,138 76.4 7,030
65yeara and over . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.71 2.24
3,971 3,435 86.5 8,650 2.18 2.52
Race
White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7,923 6,226 78.6 14,545
Black . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.84 2.34
1,510 1,290 85.4 2.774 1.84 2.15
Problem status
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 871 602 69.2 1,019
Old problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.17 1.69
8,680 6,990 80.5 16,477 1.90 2.36
Mejor reason for visit
Acute problam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,087 879 80.9 1,831
Chronic problem, routine . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.68 2.08
7,122 5,660 79.5 12,962





Post surgery/post injury . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.53 2.95
*117 *39 *33.6 *95 *.81 *2.44
Non-illness care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 419 *324 “77.3 *674 *1 .37 *1 .77
1A “i~]t in ~hi~h one or more drugswere ordered or provided.
2DrUg ~ention5 divided by number Of visits.
3Drug ~entio”~ divided by numbar Of drug visits.
b,nclude~ ~aceS Oth~r than white and black not shown as sersarata cata90ries.
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Table6. Number and percent distribution of office viaits for diabetea mellitus by number of medication, according to selected characteristics: United States, 1980
Number of medications
All visits






8othsexea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Female, ., . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Male, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age
Under 45 years. , ., ., ., .,.,.... . . . . . . . . . . . . . . . . . . . . .
45–64 yeara. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
65 years and over . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Race
White ., ., . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Black . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Problem status
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Old problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mejor reason for viait
Acute problem, ., . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, routine. .,..... . . . . . . . . . . . . . . . . . . . . .
Chronic problem, flareup. .,.... . . . . . . . . . . . . . . . . . .






















































































1 Includes races other than white and black not shown as SeParat@ Cate90~es.
Table 7. Number, percent distribution, and rate per 100 viaita of drug mentions in office visits for diabetes mellitus by therapeutic category,





Under 45-64 65 years
45 years years and over
Therapeutic categoryl
Number of mentions in thousands
All therapeutic categories .,.... . . . . . . . . . . . . . . . . . . . . 17,496 Ii<loo 6,396 1,817 7,030 8,650
Percent distribution
Total. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100.0 100.0 100.0 100.0 100.0 100.0
Cardiovascular drugs.......,.,.. . . . . . . . . . . . . . . . . . . . . 18.5 17.8 19.8 “6.0 17.9 21.7
Central nervous system drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.4 9.7 “8,9 *8.8 *8.5 10.2
Electrolytic, caloric, and water belance. . . . . . . . . . . . . . . . . . . . 14.8 15.5 13.6 *6.7 15.4 16.1
Hormones and synthetic substitutes . . . . . . . . . . . . . . . . . . . . . . 39.8 38.0 42,8 57.9 38.3 37.2
Another therapeutic cetegoriea. . . . . . . . . . . . . . . . . . . . . . . 17.5 19.0 14.9 20.6 19,9 14.8
Drug mention rate per 100 visits
Cardiovascular drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34 35 33 *7 31 47
Central newous system drugs.... . . . . . . . . . . . . . . . . . . . . . 17 19 15 “11 *15 22
Electrolytic, caloric, and water balance. . . . . . . . . . . . . . . . . . . . 27 30 23 “8 26 35
Hormones end synthetic substitutes. . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 74 71 71 66 81
1 Based ~“ the ~lsSSifi~ation System Of the American Hospital Formulav service. See reference 5
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Table 8. Number and percent distribution of drug mentions in office visits for diabetes mellitus by most frequently mentioned specific drugs described by
principal generic ingredient(s) and principal therapeutic catego~ United States, 1980
Name of drugl Drug mentions Principal generic ingredient Principal therapeutic catego~
All drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Insulin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diabinese . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Orinase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tolinase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lasix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dyazide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Aldomet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lanolin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dioxin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .





































insulin and anti-diabetic egents
insulin snd anti-diabetic agents
insulin and anti-diabetic agents







1 Bs~ed on the phy~i~ian-s .snt~ on ths Patient Record form. The entry may bes brand or 9eneric nsme.
Zlfo”lyo”e ~enefic i“gredie”t is li~ted, the Phy~i~ia”Js e“t~ isthege”aric drug ors brsnd name drug thst consistachieflyof a SiI’@ generic ingredient. fJaynot includeaIl ingredientsfor
evew combination drug.
3Based on the classification system of the American Hospitsl Formulary Service. See reference 5.
Table 9. Number and percent distribution of druga used in office visits for diabetes mellitus by form of use, according to most frequently used









Chlorpropamide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Digoxin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Furosemide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hydrochlorothiazida . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Insulin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methyldopa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tolazamida . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tolbutamide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .























Table 10. Number of office visits for obesity snd other hyperalimentatiom number and percent of drug visits, number of drug mentiOns, drug mention rste,







All visits Drug visitsq rate2 rate3
Sex
Both sexea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Female, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Male . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age
Under 25 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25-44 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45years snd over . . . . . . . . . . . . . . . . . . . . . . . . . . .
Race
White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Black . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Problem status
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Old problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Major reason for visit
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, routine . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, flareup . . . . . . . . . . . . . . . . . . . . . . . . .
Post surgetylpost injuv . . . . . . . . . . . . . . . . . . . . . . . . . . . . .














































































*1 .56 “1 .86
1.63 2.23
1A “i~h in which one or more drugs were ordsrsd or provided.
.’2Drug ~e”tions divided by numbsr Of visits.
3Drug ~sntio”~ divided by number of drug visits.
41”c,udes ~aceS other thsn white and blsck not shown as separate cste90~es.
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Table 11. Number and percent distribution of office visits for obesity and other hyperalimentation by number of medications, according to
selected characteristics United States, 1980
Number of medications
Selected characteristic All visits




Sex thousands Percent distribution
Both sexes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .























Under 25 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25-44 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .























White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
















New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .















Major reason for visit
Chronic problem, routine . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-illness care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .






















1 ,nclude~ ~sce~ other thsn white and black not shown as separate cate90ries.
Table 12. Number, percent distribution, and rate per 100 visits of drug mentions in office visits for obesity and other hyperalimentation by therapeutic cate90V’,





Under 25-44 45 years
25 years years and over
Therapeutic catego/






*1 4.7 *1 3.0
*22.6 *1 5.9




All therapeutic categories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15,070 13,152 9.346 4.596
Total, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Central newous system drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Electrolytic, caloric, and water balance. . . . . . . . . . . . . . . . . . . . . . . . . .
Hormones and synthetic substitutes. . . . . . . . . . . . . . . . . . . . . . . . . . . .

































Central newoussyatem drugs... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Electrolytic, caloric, and water balance. . . . . . . . . . . . . . . . . . . . . . . . . .
Hormones and synthetic substitutes. . . . . . . . . . . . . . . . . . . . . . . . . . . .
1 ~a~ed on the cla~~ification system of the American Hospital Formulav se~ice. sea refarence 5,
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Tabla 13. Number and percent distribution of drug mentions in office viaita for obesity and other hyperalimentation by most frequently mentioned specific
drugs dascribed by principal generic ingredient(s) and principal therapeutic categow United States, 1980
Name of drug~ Drug mentions Principal generic ingrediant(s)z Principal therapeutic categor#
All drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chorionic gonadotropin . . . . . . . . . . . .
Lasix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ionamin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hydrochlorothiazide . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fasten. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Thyroid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vitamin B-l Z . . . . . . . . . . . . . . . . . . . . . . .
Phentermine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Didrex . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tenuata . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dextroamphetamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Phenylpropanolamina . . . . . . . . . . . . . . . . . . . . . . . . . . . . .















































respiratory and cerebral stimulants
diuretics
respiratory and cerebral stimulants
thyroid and antithyroid
vitamin B complex
respirato~ and cerebral stimulants
respirato~ and cerebral stimulants
respirato~ and cerebral stimulants
respirato~ and cerebral stimulants
sympathomimetic agents
1 Based on the phy~i~ian,~ ~ntv On the Patiant Record Form. The entry maY be a brand or 9eneric ‘ame.
21f ~“ly ~“e genaric i“9redient is listed, the phy~icia”.~ e“tw is the ~e”etic drug ora brand name drug that consists chieflyofa sin91e9eneric ingredient.May not includeall in9redientsf0r
every combination drug.
3Ba~ed on the ~las~ificatj~” ~y$tem of the American Hospital FormularySe~ice. See referenca 5.
Table 14. Number and percent distribution of drugs used in office visits for obesity and other hyperalimentation by form of use, sccording to most frequently











Benzphetamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chorionic gonadotropin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dextroamphetamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diethylpropion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Furosemide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hydrochlorothiazide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Phendimetrazine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Phentermina . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Thyroid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


































Section IIL Neurotic disorders
or depressive disorder, NECC
This pair of diagnoses (ICD-9-CM 300 and 3 11),
representing 13.7 million visits, had the lowest illness-
related drug mention rate (0.88) (table 15) compared
with others shown in table 1. Only 52 percent of visits
included one or more drugs (table 15), with no statis-
tically significant difference between proportions of
drug visits or rates for women and men. However, the
proportions of drug visits increased with each advanc-
ing age group ranging from 33 percent of visits by pa-
tients under 25 years of age to 85 percent of those 65
years of age and older. Drug visits were also propor-
tionately more frequent when patients presented new
problems (66 percent) than when they returned for care
of an old problem (49 percent). Drug visits were also
more common when the major reason for visit was an
acute problem (65 percent) or a flareup of a chronic
problem (65 percent) than when it was a routine visit for a
chronic problem (45 percent). These findings suggest a
conservative use of drugs during ambulatory care ofilce
visits.
Psychotherapy or therapeutic listening was used in
proportionately more visits (69 percent) than drug ther-
apy was (52 percent). When psychotherapy was used,
59 percent of those visits did not include medication
therapy.
For all drug visits, one was the most likely number
of medications since the 29 percent of visits in this
category was the highest proportion in the categories
greater than zero (table 16). One drug was also pre-
eminent in new problem visits (42 percent). The rela-
tively high proportion of visits with no medication pre-
scribed when the major reason for visit was a routine
chronic problem suggests a decreased use of medication
as the course of treatment progressed.
In 87 percent of all drug visits the prescribed drugs
were in one or both of two central nervous system thera-
peutic categories: psychotherapeutic agents or sedatives
and hypnotics. The drug mention rates of these two
groups are detailed by sex and age of the patient in table D.
cNot elsewhere classified.
Table D. Drug mention rate per 100 ofFice visits for neurotic disorders or
depressive disorder, NEC,l for all central nervous system drugs and
selected subcategories by sex and age of the patient United States, 1980
All central Psycho- Sedatives
Sex and age nervous system therapeutic and
drugs2 agents hypnotics
Sex Rate per 100 visits
Female . . . . . . . . . . . . . . . . . 66 33 27
Male . . . . . . . . . . . . . . . . . . . 52 26 22
Age
Under 25 years . . . . . . . . . . *32 *17 *11
25-44 years . . . . . . . . . . . . 46 23 20
45-64 years . . . . . . . . . . . . 79 44 30
65 years And over . . . . . . . . 112 41 51
1 ~EC= not .gsewhere classified.
Z]ncludes analgesics and LiINiPYMk
Female patients were more likely to receive central
nervous system drugs than male patients. The rate of
sedatives and hypnotics (for example, tranquilizers)
increased with the patient’s advancing age group, but
differences among age groups using psychotherapeutic
drugs (for example, mood altering drugs) were not sta-
tistically significant.
Eight specific drugs in these two categories ac-
counted for 36 percent of all drug mentions (table 17),
Valium (9 percent), Tranxene (4 percent), Ativan (4
percent), and Librium (3 percent) were the leading
drugs in the sedatives and hypnotics class. Elavil (7
percent), Sinequan (4 percent), Triavil (3 percent), and
Tofranil (3 percent) were the most commonly prescribed
psychotherapeutic agents. The list of generic substances
in table 18 directly reflects these eight drugs. The
amount of the generic substance used is higher than the
number of mentions of the entry in table 17 by that
generic name. That may be because another brand name
drug with the same generic ingredient used singly or in
combination with other ingredients was less frequently
prescribed, or because infrequently the physician en-
19
tered the name of the generic substance. In both in-
stances the substance would be included in table 18 but
not in table 17. As has been evident in previous tables,
this tends to change the ranking somewhat. In table 17
the number of mentions of Valium (diazepam) is higher
than that of Elavil (amitriptyline), but in table 18 ami-
triptyline leads diazepam. These data provide alternative
approaches to analysis depending on the research needs.
It was shown in table 4 that federally regulated
drugs accounted for about one third of the drugs pre-
scribed in the presense of neurotic disorders or depres-
sive disorder, NEC. Of these 3.9 million mentions, 92
percent were in schedule IV (table E, see section I for a
description of the Drug Enforcement Administration
scale). Of the drugs listed in table 17, those in the
therapeutic category of sedatives and hypnotics are in
schedule IV; the others are not federally regulated.
Table E. Number and percent distribution of federally controlled drug
mentions in office visits for neurotic disorders or depressive disorder,




Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,880
Percent distribution
TotsI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100.0
Schedule I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.0
Schedule 11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.6
Schedule ill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.5
Schedule IV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91.7
Schedule V . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.2
1 NEC = not elsewhere classified.
2Based ~nthe ~lassification system of the Drug Enforcement Agency of the Department Of
Justice,
Table 15, Number of office visits for neurotic disorders or depressive disorder, NEC,l number and percent of drug visits, number of drug mentions,







All visits Drug visits2 rate3 rate4
Sex
Both sexes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Male . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age
Under 25 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25–44 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45–64 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
65 years and over . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Race
White. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Black . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Problem statua
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Old problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Major reason for visit
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, routine . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, flareup . . . . . . . . . . . . . . . . . . . . . . . .
Poatsurgery/post injuw . . . . . . . . . . . . . . . . . . . . . . . . . . . . .























































































1 NEC = not elsewhere classified.
2A “i~it in which one or more drugs were ordered or provided.
3Drug mentions divided by number of visits.
4Drug mentions divided by number of drug visits.
Slncludes ~a~e~ other than white and black not shown as separate cate90tieS.
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Table 16. Number and percent distribution of office visits for neurotic disordera or depressive disorder, NEC,l by number of medicetiona,
according to selected characteristics United States, 1980
Number of medications
Selected characteristic All visits




Sex thousanda Percent distribution
Both sexea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213,652 100.0
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9,029 100.0






























































Under 25 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25-44 yeara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45-64 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .










White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .






New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .





Major reason for visit
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, routine . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, flareup . . . . . . . . . . . . . . . . . . . . . . . . . . . . .









1 ~Ec= not .gI$ewhere classified.
zrnclude~ ~aces Other than white and black not shown as sermrata cate90ries.
Table 17. Number and percent distribution of drug mentions in office viaits fbr neurotic disorders or depressive disorder, NEC,l by most frequently
mentioned specific drug described by principal generic ingredient(a) and principal therapeutic catego~ United States, 1960





All druga . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11,951 100.0 . . . . . .
Valium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Elavil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tranxene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sinequan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ativan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Triavil :
tibrium: ::::::::::::::::::::: :::::::::::::::::::::
Tofranil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .



































1 NEC = not elsewhere classified.
z~a~ed on the phy~i~i~n<s ~ntv on the Patient Record Form. The entrf maybe a brand Or 9anaric name.
31f ~“lyone ~e”eric i“9redient is ]i=ted, tha Phy~ieian.s .S”tw is the genefic drug LXa brand name drug that consists chiefly of a single gi3WriC ingredient. May not include all ingredients for
ava~ combination drug.
‘t~ased ~“ the ~la~~ification system Of the American Hospital FormuW SeNice. See reference 5.
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Table 18. Number and percent dwtribution of drugs used in office visits for neurotic disorders or depressive disorder, NEC,l by form of use,










thouaanda Percent distribution “
Amitriptyline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,513 100.0 68.3 31.7
Chlordiazepoxide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 664 100.0 58.3 41.7.
Clorazepate. .,,.........,.,.,.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 599 100,0 100.0
Diazepam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,060 100,0 100.0
Doxepin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 607 100.0 100.0
lmipramine, . ., . . . . . . . . . . . . . . . . . . . ...,,,,,.,,,........,.,,,,,,,,, , .,,,,,,,, 454 100.0 100.0
Lorazepam, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 425 100.0 100.0
Perphenazine, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 503 100.0 4.4 95.6





Patients with this diagnosis made 25.1 million visits,
the highest number of visits for an illness-related diag-
nosis in 1980. During these visits there were about 46.5
million mentions of drugs for an average of 1.85 drug
mentions per visit (table 19).
The drug mention rate for women (1.92) was sig-
nificantly higher than that for men (1.72), and drugs
were more likely to be used for patients 45 years of age
and older than for younger patients. However, the dif-
ference between rates for patients 45–64 years of age
(1.84) and older patients (1.9 1) was not statistically
significant.
Almost all visits were made by patients the physi-
cian had treated previously for the same problem (91
percent), and 9 of 10 such visits included medication
therapy. When hypertension was presented as a new
problem, drugs were less likely to be used, since about
79 percent of such visits included medication therapy
compared with 90 percent in old problem visits. There
was little variation in drug intensity rates among the
variables listed in table 19 with averages hovering
around 2.0.
It is shown in table 20 that one drug ordered or
provided was the most likely event with 36 percent of
the visits in that category. In another 27 percent of
visits, two drugs were mentioned. Proportions of visits
decreased as the number of drugs prescribed during a
visit increased.
Drug mentions are shown by therapeutic categories
in table 21. The majority of drug mentions were in two
classes: hypotensive agents (24 percent) and diuretics
(30 percent). Another 8 percent were cardiac drugs.
Some beta-adrenergic blocking agents classified as car-
diac drugs by the American Hospital Formulary Ser-
vice (for example, propranolol and nadolol) are used to
treat angina pectoris and other heart conditions as well
as hypertension, thus increasing the proportion of car-
diac drugs used with hypertension.
Among all therapeutic categories, only the differ-
ence between the drug mention rates of women and men
who were prescribed central nervous system drugs was
statistically signiilcant. The small differences in rates of
other categories were probably due to sampling varia-
bility.
A wide variety of drugs were used in hypertension
visits. The 30 drugs listed in table 22 accounted for
about 60 percent of all drug mentions. The reader is
cautioned that the ranking may be somewhat artificial
because some estimates do not differ significantly from
other near estimates due to sampling variability. Of the
30 listed drugs, 10 are hypotensive agents, 9 are di-
uretics, 4 are cardiac drugs, and 2 are potassium re-
placement solutions. Only one is a tranquilizer. Dyazide
(6 percent) and Hydrochlorothiazide (5 percent) were
the most frequently prescribed drugs. Aldomet was the
leading hypotensive agent (5 percent). Inderal (pro-
pranolol), a cardiac drug often used as an antihyperten-
sive, also accounted for 5 percent. There were also
415,000 mentions of influenza virus vaccine and 303,000
mentions of Vitamin B-12, which suggests that pre-
ventive medicine was practiced during visits by at-risk
patients.
The Joint National Committee on Detection, Eval-
uation, and Treatment of High Blood Pressure recom-
mends a “stepped-care” approach to drug therapy. In
their four-step sequence, step 1 is a diuretic and step 2 is
the addition of an adrenergic inhibiting agent (classified
as hypotensive agents in this report).11 The degree of
compliance with steps 1 and 2 of the committee’s recom-
mendation may be estimated from National Ambula-
tory Medical Care Survey (NAMCS) data. Visits for
hypertension were examined to determine how many
included a diuretic without a hypotensive agent (although
other drugs may have been listed), a hypotensive agent
without a diuretic, both types of drugs in one visit, or
neither one. The results are shown in table F. In about
one quarter of all visits, neither of these therapeutic
categories was mentioned. The proportionately largest
group, about 29 percent, included a diuretic only, 24
percent had a hypotensive agent only, and 22 percent
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Table F. Percent distribution of drug visits for essential hypertension by concomitance of two therapeutic categories, according to sex and age of patient
and problem status: United Statas, 1980
Therapeutic categoryl








8oth sexes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100.0
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100.0
Male . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100.0
Age
Under 45 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100.0
45–64 yeara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100.0
65 years and over . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100.0
Problem status
New problem, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100.0


























1 Based on the c{assificstio” system of the Americsn Hospital Formulaw seWiCe. see referenca 5.
21”clUde~propra”oIoI,which is classified s cardiac drug by the American Hospital Fo~uW ‘emice
included both a diuretic and a hypotensive agent. Women
patients were more likely to use a diuretic alone than a
diuretic with a hypotensive agent, but the difference
between these two categories for men was not statis-
tically significant. A higher proportion of visits fell in
the diuretics only group than in the dual category when
patients visited for new problems. This suggests a de-
gree of compliance with the recommendation to use a
diuretic without other drugs in the early stage of treat-
ment. The predominance of the diuretic only category
did not change for different age groups.
It is apparent from the repetition of generic descrip-
tors shown with the drug entries listed in table 22 that
some brand name drugs consist of the same generic
substances as others. The most frequently utilized ge-
neric substances are shown in table 23. Hydrochloro-
thiazide (10.5 million uses) was clearly the most fre-
quently used generic ingredient.
Ischemic heart disease
There were 10.4 million visits for ischemic heart
disease (table 24). The number of visits by men (59
percent) exceeded those by women(41 percent). This is
one of the few conditions not related to the sex of the
patient found in NAMCS where the visit rate of male
patients exceeded that of female patients. However,
higher visit rates do not necessarily portend higher drug
mention rates since there was no statistically significant
difference betwen the rates of the two sexes. But the
drug mention rate of 2.54 and the drug intensity rate of
2.93, regardless of sex, were higher than any other rates
in this report.
Age of the patient was a more influential variable in
the use of medication therapy than the sex of the patient.
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Patients 65 years and over were more likely to have
drugs prescribed than younger patients were, and the
average number of drugs per drug visit was also higher
for older patients.
About 88 percent of all visits were made by patients
returning for care of old problems, and their drug men-
tion rate of 2.62 was signiilcantly greater than the rate of
2.00 for patients with new problems. When the return
visit was caused by a flareup of a chronic problem rather
than a routine return visitor an acute problem, medica-
tion therapy was proportionately more frequent. About
95 percent of visits due to a flareup of a chronic con-
dition includeddrugs compared to 86 percent of visits of
a more routine nature. The mean number of medica-
tions during drug visits necessitated by the ir~tensifica-
tion of a chronic problem was 2.89, higher than the
average number for all visits.
me high drug rates associated with this diagnosis
were due to the relatively large proportions of visits with
three, or four or more drugs (table 25). On the average,
20 percent of the visits included three drugs and 29
percent included four or more, a total of 49 percent in
the highest categories of drug mentions. This total ex-
ceeded that of any other diagnosis in this report. This
was particularly evident in the oldest age group with a
total of52 percent of the visits in the two highest medi-
cation categories.
Predictably, 53 percent of all medications used with
ischemic heart disease were cardiovascular drugs (table
26). This therapeutic category constituted a larger pro-
portion of visits by male patients (56 percent) than by
female patients (48 percent), but the differences by age
were not statistically significant. Diuretics were also
prominent among therapeutic categories and accounted
for 13 percent of drug mentions. This class of drugs con-
stituteda largershareof mentionsfor patients65 years
of age andolder thanit did for youngerpatients.
Table 27 shows that 15 drugs enteredon Patient
Record Forms by physicians whose patients had
ischemic heartdisease constituted57 percentof their
mentions.Threecardiacdrugs-Inderal, Lanoxin, and
Digoxin-accounted for21 percent.As mentionedpre-
viously,thebeta-blockerInderaliswidelyusedfor both
essentialhypertensionandischemicheartdisease.This
is substantiatedintables22 and27. Another20 percent
comprised the vasodilatingagents—Isordil,Nitrogly-
cerin, Nitr-bid, Nitrostat,and Sorbitrate.Lasix, Dy-
azide, and Hydrochlorothiazidewere the most promi-
nentdiuretics,totalingabout9 percentof drugmentions.
Aspirin,Vaiium, andCoumadin(2 percenteach) were
alsoamongthedrugsmostfrequentlyprescribed.About
1 percentof mentionswere influenzavirusvaccine.




the leadingsubstancesused in cardiac drugs.
Table 19. Number of office visits for essential hypertension, number and percent of drug visits, number of drug mentions, drug mention rate,









Drug visitsl rate2 rate3
Sex
Both sexes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Male . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age
Under 45 yeare. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45-64 yeara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
65 years and over . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Race
White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Black . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Problem status
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Old problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Major reason for visit
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, routine . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, flareup . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Post surgery/pOst injury . . . . . . . . . . . . . . . . . . . . . . . . . . . . .




















































































1A “i~it in which one or more drugswere ordered or provided.
2Drug ~antions divided by number Ofvisits.
3Dmg ~a”tion$ divided by number of dru9 visits.
41”c[ude~ra~es other than white and black flOt shown as Separate cste90ries
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Table 20. Number and percent distribution of office visits for’essential hypertension by number of medication, according to selected characteristics
United States, 1980
Number of medications
Selected characteristic All visits




Both aexea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Male, ...,.,..............,.. . . . . . . . . . . . . . . . .
Age
Under 45 years. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45–64 yeara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
65 years and over . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Race
White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Black . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Problem atatua
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Old problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Major reason for visit
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, routine . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, flareup . . . . . . . . . . . . . . . . . . . 1 . . . . . . . . .
Post surge~/poat inju~ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-i llneas care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Number in
thousanda Percent distribution
‘25,137 100.0 11.4 35.5 27.4
15,787 100.0 10.0 34.6 28.0
9,350 100.0 13.6 36.8 26.5












00.0 9.6 36.0 27.9
00.0 11.9 32.3 27.6






























. . . . .
*11.9 *2.9
1 ,nclu~es raceS other than white and black not shown m separate cate90~=.
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Table 21. Number, percent distribution, end rate per 100 visits of drug mentions in office visits for essential hypertension by therapeutic category,






Under 45-64 65 yeara
45 years years end ovar
All therapeutic categories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cardiovascular drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hypotenaive agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cardiac druga . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vesodilating agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Central netvoua system drugs, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analgeaica andantipyretica . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sedatives and hypnotics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Psychotherapeutic agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Electrolytic, caloric, and water balance . . . . . . . . . . . . . . . . . . . . . . . .
Diuratics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Replacement solutiona . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gastrointestinal drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hormonea andsynthetic substitutes . . . . . . . . . . . . . . . . . . . . . . . . . .
Another therapeutic categories.. . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cardiovascular drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hypotansive agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cardiac drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vasodilating agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Central newous system drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analgesics andantipyretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sedatives and hypnotics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Psychotherapeutic agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Electrolytic, caloric, and watar balance. . . . . . . . . . . . . . . . . . . . . . . .
Diuretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Replacement solutions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gastrointestinal drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .





















































































































































1 Ba$~d on the ~la~aificati~n system Of tha American Hospital Formulaw Service. sea rafar.nce 5.
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Table 22, Number and percent distribution of drug mentions in office visits for essential hypertension by moat frequently mentioned specific drugs
described by principal generic ingredient(s) and principel therapeutic categow United States, 1980





































































































































1 Based on the phy~ieia”,~ ~ntv On the patient Record Form. The entry maY be a brand Or 9erieric ‘ame,
21f only ~“e ~e”eric ingredient is listed, the ~hY~i~ia”,s ~ntw is the genetic drug ora brand name drug that consists chiefly Of a 6in91e 9eneric ingredient. Mw not includeall in9redientsf0r
every combination drug.
3Ba~ed on the classification system of the American Hospital Formulaw Service. See reference 5.
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Table 23. Number and percent distribution of drugs used in office visits for essential hypertension by form of use, according to most frequently









Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chlorothiazide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chlorthalidone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Clonidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diazepam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Digoxin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Furosemide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hydralazine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hydrochlorothiazide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ibuprofen, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Metoprolol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methyclothiazide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methyldopa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Metolazone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Nadolol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prazosin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proprsnolol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rauwolfia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Reserpine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Spironolactone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .















































Table 24. Number of office visits for iachemic heart disease, number snd percent of drug visits, number of drug mentions, drug mention rate,









Drug visitsl rate2 rate3
Sex
Both sexes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Male . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age
Under 45 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45-64 yaara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
65 years and over . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Race
White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Black . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Problem status
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Old problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Major reaaon for visit
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, routine . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, flareup . . . . . . . . . . . . . . . . . . . . . . . . . . . .
POstsurgery/pOat injuw . . . . . . . . . . . . . . . . . . . . . . . . . . . . .



















































































1A “i~it in which one or more drugswere ordered or provided.
2Drug ~ention~ divided by number Ofvisi~,
3Drug ~ention~ divided by number of drug visits.
41nclude~ra,.es Otherthan ~hits a“d black n~I shown as separate Categories, I
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Table 25. Number and percent distribution of office visits for ischemic heart diseese by number of medications, according to selected characteristics
United Ststea, 1980
Number of medications
Selected characteristic All visits




Sex thousands Percent distribution
Both saxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110,430 100.0 13.3
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,249 100.0 10.9
Male . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,181 100.0 15.0
Age
Under 45yesra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45–64yaars . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
65yeara andovar . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Race
White, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Black . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Problem status
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Old problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Major raason for viait
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic pmblem,m urine . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, flareup . . . . . . . . . . . . . . . . . . . . . . . . .
POatsurgery/post in jury . . . . . . . . . . . . . . . . . . . . . . . . . . .










































































*15.9 *2 I .3
20.5 29.9
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Table 26. Number, percent distribution, and rate per 100 visits of drug mentions in office visits for ischemic heart disease by therapeutic category,






Under 45-64 65 years
45 years years and over
All therapeutic categories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cardiovascular druga . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cardiac drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hypotensive scents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vasodilating agenta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Central newous system drugs.... . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analgesics andantipyretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sedatives and hypnotica . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Electrolytic, caloric, and water balance . . . . . . . . . . . . . . . . . . . . . . . .
Diuretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hormones andsynthetic aubatitutes. . . . . . . . . . . . . . . . . . . . . . . . . . .
Allothertherapeutic categories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cardiovascular druga . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cardiac druga . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hypotensive agenda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vasodilating agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Central nervoua aystem druga . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analgesics andantipyretica . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sedatives and hypnotics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Electrolytic, caloric, and water balance . . . . . . . . . . . . . . . . . . . . . . . .
Diuretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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1Based on the classification system of the American Hospital Formularysewice. see refarence 5.
Table 27. Number and percent distribution of drug mentions in office visita for ischemic heart disease by most frequently mentioned specific drugs
described by principal generic ingredient(s) and principal therapeutic catego~ United States, 1980
Name of drugl Drug mentions Principal generic ingredient Principal therapeutic catego$
All drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inderal,Sordil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . ..- . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Nitroglycerin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lanolin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lasix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Digoxin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dyazide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Nitro-bid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Valium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Nitrostat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Coumadin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sorbitrate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
influenza virus vaccine, type A,B. . . . . . . . . . . . . . . . . . .
Hydrochlorothiazide . . . . . . . . . . . . . . . . . . . . . . . . . . . . .







































































1 ~a~ed on the phy~i~ian.s entv On the Patient Record Form. The entry may be a brand or 9eneric name.
21fonlyo”e ~ener~ in9radient is ,i~ted, the phy~i~ian~ entv is the ge”e~c drug ~ra brand name drug that con.$i$ts chiefly of a single generic ingredient. May not include al[ ingredients for
every combination drug,
3Ba~ed ~n the ~la~~ifi~atio” system of the American Hospital Formularf SeNice. See reference 5.
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Table 28, Number and percent distribution of drugs used in office visits for ischemic. heart disease by form of use, according to most frequently used


































Section V. Otitis media and
selected respiratory diseases
Suppurative and unspecified otitis media
Children under 3 years of age were the patients in 43
percent of the estimated 11.7 million visits for otitis
media, and children 3– 14 years of age accounted for 37
percent—a total of 80 percent of visits by patients under
15 years of age (table 29).
The drug mention rate for the youngest group ( 1.56)
was not significantly higher than that of patients 3– 14
years of age ( 1.46); however, if the patient was 15 years
of age or older, the drug mention rate ( 1.67) was higher
than that of patients 3– 14 years.
Visits were about evenly divided between new and
old problems, but 94 percent of new problem visits
included drugs compared to only 78 percent of return
visits. Some of the latter group were probably followup
visits in which medication was discontinued.
In most of the visits the diagnosis shown on the
Patient Record Form did not indicate whether the pa-
tient’s case of otitis media was acute or chronic (that is,
almost all were coded as ICD-9–CM 382.9, unspeci-
fied). However, table 29 shows that in about 77 percent
the major reason for the visit was described as an acute
problem, and 90 percent of those visits included medi-
cation therapy.
Five therapeutic categories incorporated about 90
percent of the drug mentions (table 30). The majority
were anti-infective agents (51 percent). These were
chiefly antibiotics. The next largest group used were
antihistamine drugs (19 percent). Skin and mucous
membrane preparations accounted for 8 percent eye,
ear, nose and throat preparations were named in 6 per-
cent and expectorants and cough preparations in 5
percent.
The entry names of 14 drugs that accounted for 86
percent of the total mentions are listed in table 31. The
most frequently named antibiotics were Amoxicillin
(15 percent), Ampicillin (10 percent), Amoxil (6 per-
cent), Penicillin (6 percent), Ceclor (4 percent), and
Larotid (4 percent). The leading antihistamine drugs
ordered were Dimetapp (12 percent) and Actifed (4
percent). Cortisporin, a topical anti-inflammatory
agent, was the fourth most frequently used drug (7 per-
cent). Amoxicillin, with over 3 million uses, ranked fust
among the generic substances used to treat otitis media
as shown in table 32.
Acute upper respiratory infection of
multiple or unspecified sites (acute URI)
Three ICD–9–CM codes (460,461, and465) were
combined to form this diagnostic grouping because the
diseases they represent present very similar symptoms
and thus medicinal use of drugs differs minimally
among them.
There were close to 17 million visits for acute URI
(table 33), and in 94 percent of them an average of 2.02
drugs were utilized (table 33). Patients 45–64 years of
age made only 12 percent of the visits, but had a higher
drug mention rate (2.54) than did patients under 15
years of age (1.65) who made 45 percent of the visits.
About 50 percent of visits by members of the older age
group included three, or four or more drugs, whereas
only 13 percent of visits by the younger group included
the same numbers (table 34).
As in most acute, self-limiting illnesses, initial
visits exceeded return visits. Visits for new problems
were about twice as many as those for old problems.
Drug rates, however, did not differ significantly in these
two situations.
The 32 million drug mentions with acute URI were
mainly (80 percent) in four therapeutic categories: anti-
histamine drugs, anti-infective agents, central nervous
system drugs, and expectorants and cough preparations
(table 35). Abroad spectrum of drugs from each thera-
peutic group was used. The relatively long list of drug
names in table 36 covers only 54 percent of all men-
tions. When sampling error is considered, many esti-
mates in this table do not differ significantly from other
near estimates. The antibiotics Penicillin, Tetracycline,
and E. E. S., which head the list, were ordered with
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almost equal frequency, and together accounted for 11
percent of mentions. Actifed (4 percent) and Dimetapp
(3 percent) were predominant among antihistamines.
Phenergan expectorant with codeine accounted for 3
percent of drug mentions with this diagnosis.
It was noted in section I that a higher than average
proportion of over-the-counter drugs was associated
with visits for acute URI. Among these nonprescription
drugs were Aspirin, Dimetane, Tylenol, Novahistine,
Robitussin, Sudafed, and Triaminic.
Generic substances are listed in table 37. Phenyl-
ephrine, phenylpropanolamine, and pseudoephedrine
are found in many drugs identified by a wide variety of
trade names. Therefore, it is not surprising to find over 3
million uses of each of these substances in medication
therapy for acute URI. This table reflects the principal
ingredients of the most frequently named drugs in table
36, but provides a more complete total use of generic
substances.
Acute pharyngitis or acute laryngitis
and tracheitis-
This diagnostic group was formed from ICD–9–
CM codes 462 and 464. Table 38 shows that about half
of the 10.3 million visits for this condition were made by
children under 15 years of age. Only 13 percent were
made by patients 45 years of age and over, but the drug
mention rate for the oldest group (1.99) was higher than
the drug mention rate for the youngest group (1.5 1).
New problem visits (6.8 million) exceeded old
problem visits (3.5 million), and almost all visits were
for acute problems (9. 3 million). However, drug rates
did not vary appreciably based on the type of visit.
Anti-infective agents accounted for 54 percent of
drug mentions. An additional 30 percent were divided
about equally among antihistamine drugs, central ner-
vous system drugs, and expectorants and cough prepar-
ations (table 35). Table 36 shows that, by entry name,
Penicillin (11 percent) and Ampicillin (7 percent) were
the most frequently mentioned antibiotics. Aspirin was
the chief central nervous system drug used (5 percent).
Antihistamines and expectorants and cough prepara-
tions are not listed among the most frequent drug men-
tions because the diversity of entry names in these
categories precluded high frequency for any one.
Table 39 shows that over 3.4 million drug mentions
were of the generic substance penicillin. Because table
36 shows that there were 1.8 million entries called
“Penicillin,” it is apparent from table 39 that there were
entries of various brand name drugs that used this same
generic substance.
Bronchitis, acute; or not specified
as acute or chronic
When acute bronchitis was specified on the Patient
Record Form as the principal diagnosis it was coded
ICD–9–CM 466, but when it was not qualified as to
acute or chronic, it was coded ICD–9–CM 490. How-
ever, there are indications that the physician intended
the diagnosis to mean acute bronchitis because the
major reason for visit in these unqualified cases was
almost always classified by the physician as an “acute
problem.” For this reason the two codes were cc~mbined
for this analysis.
Of the 8.3 million visits for bronchitis, 53 percent
were made by female patients and 47 percent by imales—
approximately the distribution of the population used
in the National Ambulatory Medical Care Survey
(NAMCS). The drug mention rate for female patients
(2.09) was higher than that of male patients (1.82).
Among age groups, proportionately more visits included
patients under 15 years of age. But the drug mention rate
of the youngest group (1.72) was the lowest of those
associated with the age groups shown in table 40.
Drugs in the therapeutic categories of anti-infective
agents (42 percent) and expectorants and cough prepar-
ations (20 percent) were the most frequently used medi-
cations (table 35). Antihistamine drugs accounted for 9
percent of drug mentions and spasmolytic agents for 6
percent. The most common treatment regimens con-
sisted of an antibiotic alone, or an antibiotic with an
expectorant or cough preparation. About33 percent of
the visits with an antibiotic noted did not include anti-
histamines or expectorants and cough preparations (al-
though other drugs may have been ordered). Both an
antibiotic drug and an expectorant or cough prepara-
tion were prescribed in 30 percent of drug visits. Treat-
ment varied depending on the age group of the patient. If
the patient was under 25 years or over 64 years of age,
an antibiotic alone was the most likely therapy. If the
patient was from 25 to 64 years old, then an antibiotic
plus an expectorant or cough preparation were likely to
be prescribed.
By entry name, the frequencies of the antibiotics
Arnoxicillin, Ampicillin, Penicillin, Tetracycline, and
Erythromychi were not very different when sampling
error was taken into account (table 36). Together they
accounted for 20 percent of drug mentions. Phenergan
and Dimetane (an over-the-counter drug) were the most
commonly named antihistamines, and totaled 7 per-
cent. Although expectorants and cough preparations
accounted for 20 percent of the drug mentions, only
Phenergan Expectorant with Codeine (prescription, 4
percent) and Robitussin (nonprescription, 2 percent)
are included in table 36. A wide variety of prescription
and over-the-counter drugs were mentioned in this cate-
gory. Thus, some individual estimates did not meet
National Center for Health Statistics standards of re-
liability. This probably reflects the availability of dif-
ferent drugs in this therapeutic category. The large re-
sidual of 65 percent, which includes many drugs with
estimates of less than 300,000, attests to the diversity of
physicians’ choices.
The generic substances most often used in drugs
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prescribed for patients with bronchitis are shown in
table 41. Except for the antibiotics, these substances
were for the most part ingredients in combination drugs.
It was shown in table 4 that about 13 percent of
drugs invisits for bronchitis were under Federal control.
Of these approximately 2 million mentions of controlled
drugs, 74 percent (or 1.5 million) were in schedule V
(the leastpotentialfor abuse and dependence). This was
due chiefly to the various antitussive drugs that included
a relatively small amount of codeine as a secondary
ingredient. Table 41 shows that codeine was an ingred-
ient in 1.4 million drug mentions, 96 percent of which
were in combination drugs.
Asthma
Patients under 15 years of age accounted for the
largest proportion of visits for asthma (39 percent of the
5.9 million visits assigned this principal diagnosis), but
theirdrug mention rate of 1.50 was the lowest of the age
groups shown in table 42. The drug mention rate in-
creased as the patient’s age group increased up to age
group 45-64 years with a rate of 2.70.
The large proportion of visits by patients returning
for care of old problems (80 percent) is characteristic of
chronic diseases. However, problem status was not a
factor in the rate of drug mentions since the difference
between new and old problem rates was not statistically
significant.
Table 35 shows that one fourth of the drugs men-
tioned were spasmolytic agents. The most frequently
mentioned specific drugs in this group were Theo-dur,
Slo-phyllin, and Marax, which together accounted for
about 10 percent of drugmentions (table 36). Autonomic
drugs(17 percent, chiefly sympathomimetic) constituted
the next largest therapeutic category prescribed. Repre-
sentative of this group were Alupent (5 percent) and
Brethine (4 percent). Although there were 1.6 million
total mentions of antihistamine drugs, there were no
specific drugs in this category that were predominant.
The adrenals, Prednisone and Vanceril, accountedfor9
percent of drugs used.
“Allergy relief or shots” was noted on about 10
percent of the Patient Record Forms, but it was not
possible to identify the allergens used.
The relatively frequent use of the generic spas-
molytic agent theophylline in treating patients with
asthma is underscored by the data in table 43. About71
percent of the 2.3 million uses was as a single ingredient
drug and 29 percent in combination drugs. Slo-phyllin
and Theo-dur are examples of the former use; Marax,
the latter. Metaproterenol and terbutaline, which are
syrnpathomimeticagents, arerepresented among specific
drugs shown in table 36 by Alupent and Brethine, re-
spectively.
Allergic rhinitis
The 8.4 million visits for allergic rhinitis shown in
table 44 were equally divided between female and male
patients, but the drug mention rate of females was
higher than that of males. Two age groups, under 15
years and 25–44 years, accounted for 30 percent and
33 percent of visits, respectively, andtheirdmg mention
rates were about the same. The highest drug mention
rate was associated with age group 45–64 years.
The major reason for two of three visitswas a routine
chronic problem with a drug mention rate of 1.14. But if
the major reason was an acute problem, the drug men-
tion rate rose to 1.51.
About 90 percent of the visits included medication
therapy and one drug only was mentioned in 76 percent
of those drug visits.
Drugs in the therapeutic category of antihistamines
accounted for 62 percent of total mentions (table 35).
As discussed previously, antihistamines are used in
such a wide variety of prescription and over-the-counter
drugs and offer so many choices to both physician and
patient that specific drug entries do not accumulate in
sufficient frequency in NAMCS to provide reliable
data. The largest number of such mentions was for
Dimetapp (table 36).
Similar to asthma visits, allergy relief or shots with-
out fimther qua.liilcation was entered as medication
therapy in 41 percent of mentions. However, ragweed
and related pollen allergens was named in 4 percent of
mentions.
Generic substances most frequently found in drugs




Table 29. Number of office visits for suppurative and unspecified otitis media, number and percent of drug visits, number of drug mentions,
drug mention rate, and drug intensity rate, by selected characteristics United States, 1980
Office visits Drug Drug
Selected characteristic Drug mention
mentions
intensity
All visits Drug visitsl rate2 rate3
Number in Number in
Sex
Number in
thousands thousands Percent thouaanda Rate per viait
Both sexes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 411,748 10,067 85.7 18,168 1.55 1.80
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,562 4,842 87.1 8,868 1.59 1.83
Male, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,185 5,225 84.5 9,299 1.50 1.78
Age
Under 3yeers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,032 4,405 87.5 7,851 1.56 1.78
3-14 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,315 3,597 83.4 6,316 1.46 1.76
15yeara and over . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,402 2,066 86.0 4,001 1.67 1.94
Race
White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11,019 9,511 86.3 17,005 1.54 1.79
Black . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 518 397 76.7 877 1.69 2.21
Problem status
New problem . . . . . . . . . . . . . . . . . . . . . 5,797 5,430 93.7 10,218 1.76 1.88
Old problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,951 4,636 77,9 7,950 1.34 1.71
Major reaaon for visit
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9,031 8,126 90.0 15,144 1.68 1.86
Chronic problem, routine . . . . . . . . . . . . . . . . . . . . . . . . . 951 556 58.4 813 0.85 1.46
Chronic problem, flareup . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,214 1,064 87.7 1,731 1.43 1.63
Post surgery/pOst in jury. ,., .,.,. . . . . . . . . . . . . . . . . . . . *154 *19 “12.2 *19 “0.1 2 *1 .00
Non-i llness care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . *398 “302 “75.8 “461 “1.16 *1 .53
1A “iSit in which one m more drugs were ordered or prOvided.
2Drug ~ention~ divided by number Of visits.
3Drug ~entionS divided by number Of drug visits.
41ncludeS rKeS other than white and black not shown as SePSr8te C2.teEOries.
Table 30. Number, percent distribution, and rate per 100 visits of drug mantiona in officie visita for suppurative and unspecified otitis media
by therapeutic category United Statea, 1980
Therapeutic categoryl Drug mentions
Number in Percent Rate per
thousands distribution 100 visits
All therapeutic categories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18,168 100.0 155
Antihistamine drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,429 18.9 29
Anti-infective agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9,265 51.0 79
Expectoranta and cough preparations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 919 5.1 8
Eye, ear, nose and throat preparations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,147 6.3 8
Skin andmucous membrane preparations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,493 8.2 13
Another therapeutic categories.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,915 10.5 16
1 Based on the classification system of the American Hospital Formulary Service. See reference 5.
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Table 31. Number and percent distribution of drug mentions in office visits for auppurative and unspecified otitis media by most frequently mentioned
specific drugs described by principal generic ingredient(s) and principal therapeutic category: United Ststes, 1980
Name of drugl Drug mentions Principal generic ingredient Principal therapeutic catego$
All drugs . . . . . . . . . . . . . . . . . . . . .
Amoxicillin . . . . . . . . . . . . . . . . . . .
Dimetapp . . . . . . . . . . . . . . . . . . . .
Ampicillin . . . . . . . . . . . . . . . . . . . .
Cortisporin . . . . . . . . . . . . . . . . . . .
Amoxil . . . . . . . . . . . . . . . . . . . . . .
Penicillin . . . . . . . . . . . . . . . . . . . .
Septra . . . . . . . . . . . . . . . . . . . . . . .
Actifed . . . . . . . . . . . . . . . . . . . . . .
Ceclor . . . . . . . . . . . . . . . . . . . . . . .
Larotid . . . . . . . . . . . . . . . . . . . . . .
Vitamin B-1 2 . . . . .. . . . . . . . . . . . .
Gantrisin . . . . . . . . . . . . . . . . . . . . .
E.E.S. . . . . . . . . . . . . . . . . . . . . . . .
Auralgan . . . . . . . . . . . . . . . . . . . . .



















































1 ~a$ed on the phy~i~ian,~ entV on tha Patient Racord Form. The ent~ may ba a brand Or9eneric ‘ame.
21fon[yo”e generic ingredient is li~ted,the physi~ia”,~~“t~ isthe generic drugora brand name drug that consists chiefly of a single generic ingredient May not include all ingredients for
avery combination drug.
s~a~ed ~“ the ~la~~ifi~ati~” system of the American Hospital Formulaw Samice. See reference 5.
Table 32. Number and percent distribution of drugs used in office visits for auppurstive and unspecified otitis media by form of use,











Alcohol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amoxicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ampicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Antipyrine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Benzocaine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Brompheniramine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cefaclor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chlorpheniramine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Erythromycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Guaifeneain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hydrocortiaone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Neomycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Penicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Phenylephrine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Phanylpropranolamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Polymixin B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pseudoephedrine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sulfamethoxazole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .






































































Table 33. Number of office visits for scute upper respiratory infections of multiple or unspecified sites (scute URI), number end percent of drug visits,







All visits Drug visitsl rate2 rate3
Sex
Both sexes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Male . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age
Under 15 yeare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15-24 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .











45-64 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,058
65yeera and over . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,345
Race
White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14,901
Beck . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,860
Problem status
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11,405
Old problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,564




























1,941 94.3 5,222 2.54 2.69
1,309 97.3 3,001 2.23 2.29
4,064 94.4 28,597 1.92 2.03
1,735 92.3 3,351 1.78 1.93
0.697 93.8 21,207 1.86 1.98
5,280 94.9 11,104 2.00 2.10
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19,706 14,866 94.7 29,926 1.91 2.01
Chronic problem, routine . . . . . . . . . . . . . . . . . . . . . . . . . . . . 414 *366 *88.5 “694 *1 .68 *1 .90
Chronic problem, flareup . . . . . . . . . . . . . . . . . . . . . . . . . . 594 554 93.3 1,431 2.41 2.58
Non-illness care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ●255 “192 *75.2 *259 *1 .02 *1.35
1A “i~h i“ which one or more drugs were ordered or prOvided.
2Drug ~e”tiona divided by number of ViSita.
3Drug ~entio”S divided by number of drug visits.
41 “clude~ ~acea other than white and black not shown as separate cate90ries.
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Table 34. Number and percent distribution of office visits for acute upper respiratory infections of multiple or unspecified sites (acute URI)
by number of medications, according to selected characteristics United States, 1980
Number of medications
Selected characteristic All visits




Sex thousands Percent distribution
Both sexes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116,969 100.0 5.8 33.8 36.0
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9,112 ~00.0 5.2 32.0 36.6
Male . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7,857 100.0 6.5 36.0 35.3
Age
Under 15 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7,677 100.0 6.8 38.9 40.9
15-24 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,295 100.0 *7.9 33.8 33.7
25-44 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,594 100.0 *3.7 33.7 34.4
45-64 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,058 .100.0 *5.7 20.1 24.6
1,345 100.0 *2.7 26.4 33.565 years and over . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Race
White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Black . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Problem status
4,901 100.0 5.6 34.1 35.2
1,880 100.0 “7.7 32.8 41.2
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11,405 100.0 6.2 34.2 36.4
Oldpmblem. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,564 100.0 *5.1 33.2 35.2
Major reason for visit
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15,706 100.0 5.4 33.8 36.5
Chronic problem, rcwtine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 414 100.0 “11 .5 *31 .1 *40.2
Chronic problem, flareup . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 594 100.0 *6.7 *31.1 “24.1
















. . . . . .
1,nclude$ races Otherthan white snd blsck not shown aa separate cate90ries.
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Table 35. Number, percent distribution, and rate per 100 visits Of dru9 mentiOna in office visits for selected resPiratW conditions
by therapeutic category United States, 1980
Respiratory condition and therapeutic categow’ Drug mentions
Acute UR1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Antihistami ne drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Anti-infective agenda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Central netvous aystem drugs.... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expectorants andcough preparatiOna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Allothar therapeutic categories.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acute pharyngitia or acute laryngitis andtracheitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Antihistamine druga . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Anti-infective agenda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Central nervous system drugs.... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expectoranta and cough medicine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Another therapeutic categories.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Bronchitis, acute; or not specified aa acute or I
Antihistamine druga . . . . . . . . . . . . . . . . .
Anti-in fective agenda . . . . . . . . . . . . . . . .
Expectorants and cough preparations . . . . .
Spaamolytic agents . . . . . . . . . . . . . . . . . . . . .





























































































1 Based on tha classification system of the American Hospital Formulaty Service. See reference 5.
Table 36. Number and percent distribution of drug mentions in office visits for selected respiratory conditions by most frequently mentioned
specific drugs described by principal generic ingredient(s) and principal therapeutic categow United Statea, 1980
Principal diagnosis and name of drugq Drug mentions Principal generic ingredient Principal therapeutic caregory3
Acute upper respiratory infections of
multiple or unspecified sites
(acute URl) . . . . . . . . . . . . . . . . . . . . . . . . .
Penicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tetracycline . . . . . . . . . . . . . . . . . . . . . . . . .
E.E.’S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Actifed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dimetapp . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Phenergan expectorant with codeine . . . . . .
Ampicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Phenergan . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amoxicillin . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dimetane . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amoxil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Erythromycin . . . . . . . . . . . . . . . . . . . . . . . . .
Rondec . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Terramycin . . . . . . . . . . . . . . . . . . . . . . . . . . .
Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Naldecon . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Novahistine . . . . . . . . . . . . . . . . . . . . . . . . . .
Benylin Syrup . . . . . . . . . . . . . . . . . . . . . . . .
E-mycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Reflex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tylenol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Drixoral . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Robitussin . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sudafed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vibramycin . . . . . . . . . . . . . . . . . . . . . . . . . . .
Triaminic . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Residual . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acute pharyngitis or acute laryngitis
.
andtracheltls . . . . . . . . . . . . . . . . . . . . . . .
Penicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ampicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pen-Vee-K. . . . . . . . . . . . . . . . . . . . . . . . . . . .
Erythromycin . . . . . . . . . . . . . . . . . . . . . . . . . .
Tetracycline . . . . . . . . . . . . . . . . . . . . . . . . . .
V-cillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
E.E.S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Reflex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Celestone . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amoxicillin . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rasidual . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acute bronchitis and bronchiolitis or
bronchitis, not specified as acute
or chronic . . . . . . . . . . . . . . . . . . . . . . . . . .
Amoxicillin . . . . . . . . . . . . . . . . . . . . . . . . . . .
Phenergan . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ampicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Penicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tetracycline . . . . . . . . . . . . . . . . . . . . . . . . . .
Phenergan expectorant with codeine. . . . .
Etythromycin . . . . . . . . . . . . . . . . . . . . . . . . .
Dimetane . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
E.E.S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Robitussin . . . . . . . . . . . . . . . . . . . . . . . . . . .

























































































































































































































expectorants and cough preparations
. . .
See footnotes at end of table.
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Table 36, Number and percent distribution of drug mentions in office visits for selected respirato~ conditions by most frequently mentioned
specific drugs described by principal generic ingredient(s) snd principal therapeutic catego~ United States, 1980—Con.
Principal diagnosis and name of drugl Drug mentions Principal generic ingredient Principal therapeutic categor#
Asthma, . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Allergy relief orshots4, .,.,..... . . . . . . . .
Alupent, . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prednisone . . . . . . . . . . . . . . . . . . . . . . . . . . .
Theo- dur . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vanceril . . . . . . . . . . . . . . . . . . . . .
Brethine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Slo-phyllin . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mars . . . . . . . . . . . . . . . . . . . . . .
Residual . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Allergic rhinitia . . . . . . . . . . . . . . . . . . . . . . . .
A[lergy relief orshots4 . . . . . . . . . . . . .
Ragweed and related pollen sllergens .
Dimetapp . . . . . . . . . . . . . . . . . . . . . . .













































1 Based on the physicia”,s ~nt~ O“ tha F%tiant Record Form. The entry msy be s brand or 9eneriC name, Or a therapeutic ‘ffect.
2.1fonlyo”e generic i“gredie”t is listed, the physicians antw is the genetic drug ma brsnd name drug that consists chiafly Of a SiI191a 9eflariC ingredient. MaY nOt include all ingredients fOr
every combination drug.
?’~ased on the classification system Of the American Hospital Formulsry Sawica. Sae refsrence 5,
4Thi~ WaS the most common mode of entry for allergy treatment.
Table 37, Number and percent distribution of druga used in office visits for acute upper respirato~ infections of multiple or unspecified sitea (acute URI)














































































. Table 38. Number of office visits for acute pharyngitia or acute laryngitis and tracheitis, number and percent of drug viaits, number of drug mentions,







All visits Drug visits; ratez rate3



















Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Male . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age
Under 15 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15-24 yea rs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25-44 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


























White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


















New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Old problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .









Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problam, routine . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, flareup . . . . . . . . . . . . . . . . . . . . . . . . . . . .













1A vi~jt in which one or more drugs were ordered or Provided.
2Dr”g ~ention~ divided by number Of visits.
3Dr”g ~e”tion~ divided by number Of drug visits.
‘+ncl”des WICeS other than white and black not shown as Separatecate90ries.
Table 39. Number and percent distribution of drugs used in office visits for acute pharyngitis or acute laryngitis and tracheitis by form of use,




























































Codeine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Erythromycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Guaifenesin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Penicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Phenylephrine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Phenylpropanolamine . . . . . . . . ..-. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Potassium guaiacolsulfonate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Promethazine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pseudoephedrine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .








“380Triprolidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Tabla 40. Number of office visits for bronchitis, acute; or not specified ss acute or chronic, number snd percent of drug visits, number of drug mentions,
drug mention rate, and drug intensity rate, by selected characteristics United States, 1980






All visits Drug visitsl rate2 rate3
Number in Number in
Sex thousands thousands Percent
Both aexes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48,323 7,855 94.4
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,382 4,237 96.7
Male . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,940 3,618 91.8
Age
Undar15yaars . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,101 2,911 93.9
15-24 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 818 783 93.2
25-44 yeara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,312 1,293 98.5
45-64 yaars, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,075 1,787 95.3
65yeara and over . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,216 1,102 90.7
Race
White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7,246 6,909 95.3
black . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 916 850 92.8
Problem status
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,012 4,837 96.5
Old problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,311 3,018 91.2
Major reason for visit
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7,203 6,941 96.4
Chronic problam, routine . . . . . . . . . . . . . . . . . . . . . . . . . . . 587 447 76.1
Chronic problem, flareup . . . . . . . . . . . . . . . . . . . . . . . . . . . . 413 *364 88.0
Post surge@ p&stinju~ . . . . . . . . . ..c . . . . . . . . . . . . . . . . “12 “12 *1 00.0
Non. illness care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . “108 *91 *84.9
Number in















“771 *1 .87 “2.1 2
*24 82.00 “2.00
’183 *1 .69 “2.01
1A visit in which o“e or more drugs were ordered or provided.
213ru9 mentions divided by number of Vi$itS.
3Drug ~enlio”~ divided by number of drug visits.
alnclude~ ~aceS Other than white and black not shown as separste Cate90ries
Table 41. Number and percent distribution of drugs used in office visits for bronchitis, acute; or not specified as acute or chronic by form of use,















































,421 100.0 10.3 89.7
,265 100.0 100,0
,056 100,0 100,0
,330 100,0 21.6 78,2
650 100,0 7.1 92.9
952 100.0 96.1 3.9
590 100.0 35.0 65.0
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Table 42. Number of office visits for asthma, number and percent of drug visits, number of drug mentions, drug mention rate, and drug intensity rate,
by selected characteristics United States, 1980






All visits Drug visitsl rate2 rate3
Number in Number in Number in
Sex thousands thousands Percent thousands Rate per visit
Both sexes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45,921 58477 92.5 11,655 1.97 2.13
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,262 2,999 91.9 6,738 2.07 2.25
Male . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,659 2,478 93.2 4,917 1.85 1.98
Age
Under 15 yeara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,335 2,126 91.0 3,495 1.50 1.64
15-24 yeara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 737 716 97.2 1,262 1.71 1.76
25-44 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,106 1,031 93.2 2,271 2.05 2.20
45-64 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,065 989 92.8 2,876 2.70 2.91
65 years and over . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 678 616 90.8 1,750 2.58 2.84
Race
White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,234 4,830 92.3 10,441 1.99 2.16
Black . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 648 607 93.8 1,134 1.75 1.87
Problem status
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,204 1,148 85.3 2,616 2,17 2.28
Old problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,717 4,328 91.8 9,039 1.92 2.09
Major reason for viait
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,653 1,518 91.9 3,243 1.96 2.14
Chronic problem, routine . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,812 2,561 91.1 5,036 1.79 1.97
Chronic problem, flareup . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,214 1,169 96.3 2,976 2.45 2.55
Non-illneaa care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . “241 *228 *84.6 *401 *1 .66 *1.76
1A “i~it in Whichone or more drugs were ordered or provided.
2Drug ~sntions divided by number of visits.
3Drug ~e”tion~ divided by number Ofdrug ‘isita.
41ncIUde~~ace~o~he~than white .md black not shown as separate cate90ries.
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Table 43. Number and percent distribution of drugs used in office viaita for aathma and allergic rhinitis by form of use,
according to most frequently used ganeric au balances: United Statea, 1980
Form of use




























































1About , o% of drug ~e”tion~ ,“ “isit~ for ~~thma could not be identified by generic substance becsuse the physician’s entW was a11er9Y relief ‘r shots.
2AbOut ~,% of drug ~e”tiO”~ i“ “i~it~ for ~llargic rhi”itis m“ld mt be identified by generic substance because the physician’s entrY was aller9Y relief or shots.
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Table 44. Number of office visits for allergic rhinitis, number and percent of drug visits, number of drug mentions, drug mention rate, and drug intensity rate,
by selected characteristics United States, 1980






All visits Drug visits~ rate2 rate3
Number in Number in Number in
Sex thousands thousands Percent thousands Rste per visit
Both sexes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48,439 7,621 90.3 10,479 1.24
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,236 3,954 93.4 5,9B4 1.41





Under 15 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15-24 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25-44 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45-64 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
































White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .














New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .













Major reason for visit
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, routine . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, flareup . . . . . . . . . . . . . . . . . . . . . . . . . . . .

























1A “i~it in Whichone or more drugs were ordered or provided.
2Drug mentions divided by number Of visits.
3Drug mentions divided by number Of drug visits.
41”clude~ raceS other thsn white and black not shown as Separate Cata90ries.
.
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Section VI. Diseases of
sebaceous glands and selected
musculoskeletal conditions
Diseases of sebaceous glands
Two forms of this condition were commonly reported
in NAMC S: acne (other than varioliformis), 8.1 million
visits, and sebaceous cyst, 2.2 million visits. As maybe
expected, 72 percent of patients visiting for acne were
under 25 years of age. When sebaceous cyst was the
specific diagnosis, 84 percent of the visits were made by
patients over 24 years of age. This distinction should be
kept in mind when interpreting the data.
Beginning with age 15 years, proportions of visits
and drug mention rates decreased as the patient’s age
group increased, reflecting the type of condition likely to
be presented (table 45). Young patients who predomi-
nantly had acne were more likely to have medication
therapy than were older patients who were likely to have
sebaceous cysts, which usually require surgery but not
necessarily drugs. (Thirty-seven percent of all visits for
diseases of sebaceous glands included office surgery).
Patients 15–24 years of age accounted for48 percent of
the visits and used an average of 2.29 drugs per visit.
The group aged 25–44 years had a drug mention rate of
1.80, and those 45 years of age and over had the lowest
rate (0.93). Only 54 percent of the visits by patients
over 45 years of age included one or more drugs com-
pared with 94 percent of those by patients in the 15-24
year old group. When drugs were provided, two was the
typical number since 44 percent of such visits included
two mentions.
Drugs were more likely to be prescribed during
continuing care for an old problem (drug mention
rate = 2.11) than when a new problem was presented
(1.58). If the major reason for the visit was aflareup of a
chronic problem, patients were given drugs at the rate of
2.39 per visit compared with 1.57 per visit for acute
problems. The relatively low rate of 0.43 when the visit
was post surgery supports the previous suggestion that
drug therapy was not commonly associated with visits
for excision of sebaceous cysts.
Table 46 shows that about 77 percent of drugs
prescribed were in four therapeutic categories—anti-
biotics (43 percent), keratolytic agents (21 percent),
anti-inflammatory agents (9 percent), and cell stimulants
and proliferants (5 percent).
Tetracycline (15 percent) and Cleocin ( 12 percent)
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were the most frequently named antibiotics as shown in
table 47. Other antibiotics entered on Patient Record
Forms were Minicin (4 percent), Erythromycin (3 per-
cent), and Achromycin (3 percent). Among the many
keratolytic agents named were Desquam-X (4 percent),
Benzac (4 percent), Panoxyl (3 percent), Persa,-gel (3
percent), and Benzagel (2 percent). (The principal in-
gredient in the last five drugs is benzoyl peroxide.)
Retin-A, from the group of cell stimulants and prolif-
erants, appeared in 5 percent of drug mentions.
The leading generic substance used was tetracycline
with 4.2 million mentions (table 48). Benzoyl peroxide,
which was the principal ingredient in at least five fre-
quently used brand name drugs, was the second most
frequent generic substance with 3.6 million uses. The
generic substance tretinoin was exclusively represented
in oi%ce visits by the brand name drug Retin-A, which
was shown in table 47.
Osteoarthritis and allied disorders
or other and unspecified arthropathies
Women made 69 percent, and patients over 45
years of age, 89 percent, of the visits for this diagnosis;
but drug mention rates did not differ significantly by sex
or age (table 49).
Similar to visits for other chronic conditions made
predominantly by the elderly, 72 percent of the visits for
osteoarthritis were return visits for care of an old prob-
lem, and drugs were more likely to be used as therapy
than when patients presented the condition as a new
problem. It was pointed out in section I that some of the
drugs may have been prescribed for conditions other
than the principal diagnosis. This is particularly true of
visits by elderly patients who tend to have multiple
chronic conditions.
One or more drugs were mentioned in 82 percent of
the visits. Of this group, 45 percent had one drug men-
tion, 24 percent had two, and 16 percent had three
(number of visits with a specific number of prescrip-
tions divided by the number of drug visits).
Table 46 shows that41 percent of drug mentions
were in the category of analgesics and antipyretics.
Cardiovascular drugs, probably used for such condi-
tions as ischemic heart disease and hypertension, which
are frequently concomitant with arthropathies, ac-
counted for 12 percent.
All of the generic substances listed in table 50,
except reserpine and hydrochlorothiazide, are categor-
ized as analgesics and antipyretics. Aspirin was the
most frequently used drug with 1 million uses. Other
frequently mentioned anti-inflammatory drugs were
ibuprofen, indomethacin, naproxin, and sulindac. The
brand name entries that represented these substances as
single ingredient drugs, in the same order, were Motrin,
Indocin, Naprosyn, and ClinoriL
Intervertebral disc disorders or
other and unspecified disorders of back
Drugs were used in only61 percent of visits for disc
and other back problems, a relatively low proportion.
Visits were evenly divided between women and men,
but the women’s drug mention rate was 1.38 compared
to 0.97 for men (table51 ). This was because about 66
percent of women’s visits included drug therapy com-
pared with 57 percent of those by men. On the average,
43 percent of drug visits had one drug mentioned, and
34 percent had two.
Patients were likely to be 25-64 years old (80
percent), and rates did not differ signitlcantly for specific
age groups.
The largest category of drugs used was analgesics
and antipyretics, which accounted for41 percent of all
mentions (table 46). Skeletal muscle relaxants consti-
tuted another 14 percent. In the first group, aspinn,
acetaminophen (with and without codeine), and phen-
acetin were the most commonly used generic substances
(table 50). In the second group, methocarbamol and
orphenadrine were the most frequent.
Tylenol with Codeine was the entry name for the
388,000 single-ingredient uses of acetaminophen with
codeine. Robaxin, with 360,000 mentions, represented
the 89 percent of use of methocarbamol listed as a single
ingredient.
About 25 percent of mentions were federally con-
trolled drugs. Table G shows that of these 1.8 million
mentions, 15 percent were in schedule II, 42 percent
were in schedule III, and 43 percent in schedule IV.
Physiotherapy was provided in 34 percent of visits
for disc and back disorders. Medication therapy was also
ordered in about 64 percent of such visits.
Sprains and strains of sacroiliac region
or other and unspecified parts of back
Characteristics of drug therapy for sprains and strains
closely paralleled those of intervertebral disc disorders
or other and unspecified disorders of back (except that
drug mention rates did not differ by sex of the patient).
Only 60 percent of the 7.4 million visits for back sprains
and strains included medication therapy (table 52), and
physiotherapy was likely to be used. With this diagnosis
53 percent of the visits included physiotherapy and in
Table G. Number and percent distribution of federally controlled drug men-
tions in office visits for intervertebral disc disorders orotherand unspeci-





Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,769
Percent distribution
Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100.0
Schedule I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.0
Schedule 11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14.6
Schedule ill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41.8
Schedule IV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43.4
Schedule V . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.2
1 ~a~ed on the ~la~sification system of the Drug Enforcement .4gencv of the Depanment
of Justice.
about half of such visits medication was also prescribed.
About 78 percent of the visits were made by patients
25–64 years of age. The relatively low drug rates were
similar for specitlc age groups. However, problem status
made a difference in the provision of drugs. The drug
mention rate for patients with new problems was 1.08
compared with 0.76 for those with old problems, sug-
gesting a decrease in drug utilization as treatment
progressed.
When patients were treated with drugs, 63 percent
of such visits had one drug mentio~ only 24 percent had
two. Drug intensity rates did not vary significantly by
sex, age, or problem status.
Drug therapy consisted mainly of the two classes of
drugs shown in table 46: analgesics and antipyretics (43
percent) and skeletal muscle relaxants (21 percent).
The classes of generic substance used to treat this con-
dition were very similar to those listed with the back
diagnosis described previously.
The 1.7 million federally regulated drug mentions
for this diagnosis are distributed by control schedule in
table H, which shows that 90 percent were in schedules
111and IV.
Table H. Number and percent distribution of federally controlled drug men-
tions in office visits for sprains and strains of sacroiliac region or othar





Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,678
p~rcent distribution
Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100.0
Schedule I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.0
Schedule 11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.8
Schedule ill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37.7
Schedule IV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52.1
Schedule V . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.4




Table 45. Number of office visits for diseases of sebsceous glands, number and percent of drug visits, number of drug mentions, drug mention rste,
snd drug intensity rate, by selected characteristics United States, 1980






All visits Drug visitsl rate2 rate3
Number in
thousanda
Number in Number in

















Under 15 yeara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15–24 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25-44 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .






















White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .










*1 .55 “1 .94
Problem statua
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .











Major reaaon for visit .
1,832 1,342 73.2 2,881 1.57 2.15
5,590 5,100 91.2 11,956 2.14 2,34
2,423 2,275 93.9 5,794 2.39 2.55
582 *154 *26.4 *252 “0.43 “1 .64
“150 *76 50.3 *98 “0.65 *1 .29
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, routine . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, flareup . . . . . . . . . . . . . . . . . . . . . . . . . . .
Post surge~/post injury . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-illness care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1A “i~it in which me or mors drugs were ordared Or provided.
2Drug ~entio”~ divided by number Of visits.
?.Drug ~e”tIonS divided by number of drug visits.
41ncludes races other than white and black not shown as separate categories.
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Table 46. Number, percent distribution, and rate per 100 visits of drug mentions in office visits by selected diagnoses and therapeutic category
United States, 1980
Diagnosis and therapeutic categoryl Drug mentions
Diseases ofsebaceous glands . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Anti biotics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Anti-inflammatory agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cell stimulants andproliferants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keratolytic agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Another therapeutic categories.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Osteoarthritis and allied disorders or other and unspecified arthropathies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cardiovascular drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analgesics andantipyretica . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diuretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Adrenals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Allothertherapeutic categories.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intamartebral disc disorders or other and unspecified disorders of back . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Skeletal muscle relaxanta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analgesics andantipyretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Allothertherapeutic categories.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sprains and strains of sacroiliac region or other and unspecified parts of back. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Skeletal muscle relaxants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analgesics andantipyretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .



































































1 ~asad on ,he ~l~~~ifi~ation ~y=tem of the American Hospital Formulaw se~ice. saa reference 5.
Table 47. Number and percent distribution of drug mentions in office visits for diseases of sebaceous glands by most frequently mentioned specific drugs
described by principal generic ingredient(s) and principal therapeutic category United States, 1980





. . .All drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tetracycline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cleocin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Retin-A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Minocin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Desquam-X . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Benzac . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Erythromycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Panoxyl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Persa-gel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Achromycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
E-mycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Benzagel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Kenalog . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Staphylococcus toxoid . . . . . . . . . . . . . . . . . . . . . . . . . .
Sumycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hydrocortisone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prednisone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Salicylic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cordran . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Zinc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .























































































1sassd on the phy~i~ian,~~“tw o“ the Patient Record Form.The entry maY be a brand or 9eneric ‘ame.
21f only one ~O”eric ingredient i= listed, the ~hYsi~ian.~ ~n~v is the generic drug ma brand nsme drug that consists chiefly of a Singlegeneric ingredient.May nOtincludeall ingredientsfor
evary combination drug.
Ssased ~“ ths classification system of the American Hospital Formulary SetViCa. See reference 5.
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Table 48. Number and percent distribution of drugs used in office visits for diseases of sebaceous glsnds by form of use, according to most frequently











Alcohol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,903 100.0 100.0
Benzoyl peroxide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,587 100.0 47.1 52.9
Clindamycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,575 100.0 100.0
Edetate diaodium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 719 100.0 100.0
Erythromycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,364 100.0 100.0
Hydrocortiaone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 878 100.0 61.2 38.8
Minocycline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 844 100.0 100.0
Predniaone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . *315 100.0 “100.0
Salicylic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 862 100.0 3.0 97.0
Sulfur (cathartic) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 677 100.0 100.0
Tetracycline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,168 100.0 99.6 0.4
Tretinoin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,072 100.0 100.0
Triamcinolone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 479 100.0 100.0
Zinc topical agenta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . “326 100.0 *88.3 “11.7
Table 49. Number of office viaits for oateoarthritia and allied disorders or other and unspecified arthropathies, number and percent of drug visits,
number of drug mentions, drug mention rate, and drug intensity rate by selected characteristic: United States, 1980






All visits Drug visitsl rate2 rate3
Sex
8oth sexes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Male . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age
Under 45 years . . . . . . . . . . . . . . . .
45-64 yeara . . . . . . . . . . . . . . . .
65yeara andcwer . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rata
White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Black . . . . . . . . . . . . . . . . . . . . . . . .
Problem atatua
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Oldprobiem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Major reaaon for viait
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, routine . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, flaraup . . . . . . . . . . . . . . . . . . . . . . . .
POatsurgepr/post injury, .,.,..... . . . . . . . . . . . . .

















































































*1 .25 *1 .96
1A “i~j~ i“ which one or more drugs were ordered or provided.
2Drug ~entio”$ divided by numbar of visits.
3orug ~entio”s divided by number of drugvisits.
41ncrudes~ace~Otherthan white and black not shown as separate cate90rias
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Table 50. Number and percent distribution of drugs used in offtca visits for selected musculoskeletal conditions by form of use, eccording to most frequently
used generic substances United States, ?980








Osteoarthritis and allied disorders or other and unspecified arthropathies
Acetaminophen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fenoprofen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hydrochlorothiazide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ibuprofen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
lndomethacin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Naproxen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Raserpine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sulindac . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intatvertebral disc disorders or other and unspecified disorders of back
Acetaminophen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acetaminophen and codeine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Caffeine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Codeine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ibuprofen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methocarbamol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Orphenadrine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Phenacetin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sprains and strains of sacroiliac region or other and unspecified parts of back
Acetaminophen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acetaminophen and codeine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Caffeine . . . . . . . . . . . . ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chiorzoxazone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Codeine . . . . . . . . . . . . . . . . ,., .,.., . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ibuprofen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methocarbamol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Orphenadrine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Phenacetin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .






































































Table 51. Number of off!ce visits for intervertebral disc disorders or other and unspecified disorders of back, number and percent of drug visita,






























Under 25 yeara . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25-44 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45-64 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
































White. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
black . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Problem status
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .











Major reason for viait
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, routine . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, flareup . . . . . . . . . . . . . . . . . . . . . . . .
post surgery/pOat in jury . . . . . . . . . . . . . . . . . . . . . . . .


























1 A “i~it in which one or more druga were ordered or providad.
2Drug ~antions divided by numbar Of visits.
3Drug ~entio”~ dividad by number Of drug visits.
41”cl”de~ ~ace~ other than ~hita a“d black not shown as separate cate90ries.
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Table 52. Number of office visits for sprains and strains of sacroiliac region or other and unspecified parts of back, number and percent of drug viaita,
numbar of drug mentions, drug mention rate, and drug intensity rate, by selected characteristics United Statea, 1980






All visits Drug visitsl rate2 rate3
Sex
Both sexes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Male . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age
Under 25 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25-44 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45-64 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
65 years and over . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Race
White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Black. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Problem status
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Old problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Major reason for visit
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, routine . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chronic problem, flareup . . . . . . . . . . . . . . . . . . . . . . . . . . . .
POstaurge~/pOat injure . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
























































































1A “iSit in which one or more drugswere ordered or provided.
2DW9 ~en~ion$ divided by number Ofvisits.
3Drug ~e”tio”S divided by number Ofdrugvi$it$.
41ncludeSraceSother than white and black IIOt shown as SePSratacSte90ries.
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Section VI 1. Selected
preventive care services
The three preventive care services presented in this
report accounted for 10 percent of all visits to oflice-
based physicians in 1980, but only 5 percent of drug
mentions. Because, as the term implies, current illness
is usually absent during preventive care visits, low drug
mention rates may be expected. However, it is also
worthwhile to examine the preventive measures taken
with such care and to note by inference what medica-
tion is not routinely prescribed for patients visiting for
non-illness care.
Health supervision of infant or child
There were an estimated 17.5 million visits by chil-
dren, of which 12.5 million, or 71 percent, were for
examination of children under 3 years of age (table 53).
About 59 percent of visits by children included
medication therapy, with a drug mention rate of 0.94.
One drug was used in53 percent of the 10.3 million drug
visits; two drugs in 36 percent. The drug intensity rate
of 1.60 reflects this pattern.
Immunization is a primary concern during early
childhood visits and it is seen in the National Ambu-
latory Medical Care Survey (NAMCS) that 67 percent
of all drug mentions were in the therapeutic category of
serums, toxoids, and vaccines (table 54). The Tuberculin
tine test, a diagnostic agent, accounted for 15 percent. It
is seen in table 55 that the most frequently mentioned
biologics were Diphtheria and tetanus toxoids and per-
tussis vaccine (26 percent); Diphtheria and tetanus
toxoids, unspecified (2 percent); Poliomyelitis vaccine,
unspecified (27 percent); Vaccination, unspecified (3
percent); M-M-R (measles, mumps, rubella virus vac-
cines, 3 percent); and Rubella virus vaccine, live (2
percent).
These data provide information on the number of
single or combination immunizing agents administered,
but it is possible that more than one type was provided
during a visit. Also, the same child maybe immunized
against disease by a series of “shots. ” NAMC S does
not provide data on such episodes; therefore, the num-
ber of immunizations should not be interpreted as the
number of immunized children.
Only one vitamin was reported with more frequency
than others. Poly-vi-flor, also used for caries prophylaxis,
was indicated in 2 percent of drug mentions.
Normal pregnancy
The estimated 26.3 million visits for prenatal care
was the highest number of visits for any one diagnosis
reported in NAMCS. The drug mention rate of 0.41 is
the lowest of those in this report (table 56). Medication
therapy was mentioned in only one of every three visits,
and one drug was the likely number prescribed since it
was indicated in 79 percent of those visits in which a
drug was mentioned.
On the average there were about six return visits for
prenatal care for each visit in which pregnancy was first
diagnosed by the physician. Drug therapy was more
likely to be used in the latter, new problem, visits(53
percent) than in return visits (30 percent). This maybe
due in part to the prescription of drugs to relieve nausea
and vomiting in the early stage of pregnancy. Bendectin,
an antihistamine drug used for this purpose, was entered
in 3 percent of drug mentions.
Vitamins, which accounted for 67 percent of drug
mentions, were the most commonly prescribed therapy
for pregnant women (table 54). Antianemia drugs were
noted in 13 percent. The vitamin preparations most
frequently named by physicians are listed in table 55. In
some cases the physician simply recorded “vitamins”
(8 percent of mentions). The most frequently named
multivitamins were Prenatal Formula (17 percent),
Matema (13 percent), Stuartnatal 1 i- 1 (7 percent),
Pramet FA (5 percent), and Natalins (5 percent).
General medical examination
As table 57 shows, only 29 percent of the 16 million
visits for general medical examination included medica-
tion therapy, a not unexpected finding. A higher propor-
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tion of visits by female patients (34 percent) than by
male patients (24 percent) included drugs. The rela-
tively low drug mention rate of 0.41, matched only by
the rate for normal pregnancy, may also be attributed to
the fact that only one drug was mentioned in71 percent
of drug visits.
Serums, toxoids, and vaccines (consisting chiefly of
poliomyelitis vaccine and diphtheria and tetauus toxoids
and pertussis vaccine) were used in 27 percent of men-
tions. The Tuberculin tine test accounted for 17 percent.
Use of these biologics was associated mainly with pa-
tients under 25 years of age. Contraceptives constituted
14 percent of all mentions with general medical ex-
aminations (20 percent of women’s mentions). Putting
this statistic into perspective requires information on
the use of contraceptives when other diagnoses were
present. Of the 7.8 million mentions of contraceptives
during women’s visits for all diagnoses, 65 percent were
found with six diagnoses: 12 percent were associated
with general medical examination; 8 percent with post-
partum care; 13 percent with contraceptive manage-
ment 22 percent with gynecological examination; 5
percent with inflammatory disease of cervix, vagina,
and vulvrq and 5 percent with dkorders of menstruation.
Table 53. Number of office visits for health supervision of infant or child, number and percent of drug visits, number of drug mentions, drug mention rate,
and drug intensity rate, by selected characteristic.% IJnited States, 1980












thousands Rate oer visit
Age
Under 3 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3-5 yeara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6-14 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15 years and over . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Race
White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Black . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Problem status
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Old problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Major reason for visit
Non-illness care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .















































































1A “i~it in which ww or mors drugs wsrs ordered or Provided.
2Drug mentions di”ided by numbsr Of visits.
3Drug Mentions di”ided by number Of drug visits.
alnclude~ ~acSS Other than white snd blsck not shown ss ssparate cats90ries.
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Table 54. Number, percent distribution, and rate per 100 viaits of drug mentions in office viaits for selected health services by therapeutic catego~
United States, 1980
Health serv;ce and therapeutic categoyl Drug mentions
Number in Percent Rate per
thousands distribution 100 visits
Heaithsupewision ofinfant orchild . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16,502 100.0 94
Diagnostic agents (for tuberculosis). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,416
Serums, toxoids and vaccines ..,... ,,, , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14.6 14
11,087 67.2 63
Another therapeutic categories. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,985 18.2 . . .
Normal pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10,755 100.0 41
Antianemia drugs .,, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,370 12.7 5
Vitamins ., ., . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7,208 67.0 27
Another therapeutic categories.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,177 20.3 .,.
Genaral medical examination, ...,.... ., . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .,,,,,,,,,,,,,,,,,,, 6,624 100.0 41
Diagnostic agents (for tuberculosis).. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,154 17.4 7
Contraceptives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 899
Serums, toxoids and vaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .,, ,,, ,,, . .,, ,, .,.,..,.
13.6 6
1,778 26.8 11
Another therapeutic categories. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,793 42.2 . . .
1 Based ~“ the ~lasslflcation system of the Arnencan Hospnal Formulay Sewice. See reference 5.
Table 55. Number and percent distribution of drugs mentioned in office visits for selected health services by most frequently mentioned specific drugs
described by principal generic ingredient(s) and principal therapeutic category United Statea, 1980
Principal diagnosis and name of drugq Drug mentions Principal ganeric ingredient Principal therapeutic categoryz
Health supewision of infant or child . . . . . . . . . . ., .,
Poliomyelitis vaccine, unspecified. ., . . . . . . ., ., .,
Diphtheria and tetanua toxoids and pertuasis vaccine .,
Tuberculin tine test,........,., . . . . . . . .
M- M-R,.,.,.,............,.,,, . . . . . . . .
Vaccination, unspecified, ,, . . . . . . . . . . . . . . .
Diphtheria and tetanus toxoids, unspecified ., ., . . . . . .
Rubella virus vaccine, live, . . . . . . . . . . . . . . . . . .
Poly-vi-flor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Residual . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Normal pregnancy, , ., .,.,..... . . . . . . . .
Prenatal formula (vitamins), .,.,.,. . . . . . . . . . . . . .
Materna l..,,,...,........,.. . . . . . . . . . . . . . . . .
Vitam!n(s), unspecified, ,,, .,.,. . . . . . . . . . . . . . . .
Stuartnatal l+ l . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pramet FA, . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Natal ins, , . . . . . . . . . . . . . . . . . .
8endectln. . . . . . . . . . . . . . . . . . .
Filibon . . . . . . . . . . . . . . . . . . . . . .
Natabec, ,,, ,,, . . . . . . . . . . . . . . .,.,.,.,,,,,,,,,,.
















































diphtheria and tetanus toxoids
and pertussis vaccine
Old Tuberculin





































1 Based ~“ the physi~ta”~ ~“tv on the Pat,e”t Record Form. The entry may be a brand or generic name, or a therapeutic effect
2Ba~ed ~“ tha ~la~scflcallo” SySW- Of the American Hospital Formulary Senme. see reference 5.
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Table 56. Number of office visits by women for normal pregnancy, number and percent of drug visits, number of drug mentions, drug mention rate,
end drug intensity rate, by selected characteristics: United States, 1980







Drug visits~ rate2 rate3
Number in Number in Number in
Age thousands thousands Percent thousands Rate per visit
Alleges . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 426,256 8.727 33.2 10,755 0.41 1.23
Under 15 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . *333 *186 *55.8 “308 “0.92 *1 .66
15-24 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11,880 4,255 35.8 5,308 0.45
25-44 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.25
13,940 4,277 30.7 5,130 0.37
45years’and over . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.20
*103 *9 *8.7 *9 *0.09 *I .00
Race
White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22,923 7,551 32.9 9,185 0.40 1.22
Black . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,868 1,014 35.4 ?,383 0.48 1.38
Problem status
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,814 2,003 52.5 2,672 0.70
Old problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.33
22,441 6,724 30.0 8,084 0.36 1.20
Major reason for visit
Acute problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,074 *374 *34.8 *532 *0.50 *I .42
Non-illness care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24,879 8,208 33.0 10,054 0.40
Other reason . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.22
“303 *145 “47.9 *169 “0.56 “1.17
1A “i~it in which Onem more drugswera ordered or provided.
2Drug mentiOn~divided by number Of visits.
3Dmg mentiOn~divided by number Of drug visits.
qlnc[ude$ ~aceS C,ther than white and black not shown as sepsrate cste90rie$.
Table 57. Number of office visits for general medical examination, number and percent of drug visits, number of drug mentions, drug mention rate,








Drug visitsl rate2 rate3
Number in Number in
Sex
Number in
thousands thousands Percent thousands Rate per visit
Both sexes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 416,078 4.732 29.4 6,624 0.41 1.40
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9,350 3,134 33.5 4,440
Male . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
0.47 1.42
6,727 1,598 23.8 2,184 0.32 1.37
Age
Under 15yaars . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,288 1,575 47.9 2,171 0.66
15-24 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.38
4,159 1,163” 28.0 1,644
25-44 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
0.40 1.41
4,638 861 18.6 983 0.21
45-64 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.14
2,612 761 29.1 1,283 0.49
65 years and over . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.69
1,381 *372 ‘27.0 *544 ‘0.39 *1 .46
Race
White . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14,313 4,459 31.2 6,175 0.43
Black . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.38
1,536 *219 “14.3 *372 “0.24 *1 .70
Problem status
New problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7,756 1,746 22.5 2,646 0.34
Old problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.52
8,322 2,986 35.9 3,978 0.48 1.33
Major reason for visit
Chmnicp roblem,r outing. . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,241 411 33.1 *61 5 0.50
Non-illness care
1.50
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14,221 4,158 29.2 5,667 0.40
Other reason . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.36
615 *163 *26.5 *342 “0.56 *2.1 o
1A “i$it i“ which one Ormore dregs were ordered or provided.
2Drug ~e”,io”s divided by number Of visits.
3Drug mentions divided by number of drug ViSits.
41”~ludeS ~aceS other than white and black nOt shown as separate cate90ries.
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Discussion
All of the drug data used in this report were derived
from the information provided by physicians in item 11
of the National Ambulatory Medical Care Survey
(NAMCS) Patient Record. Part a of this item was
designed to elicit the medication prescribed for the prin-
cipal diagnosis assigned to the patient’s visit. Part b was
provided to list medication ordered for all other reasons.
In order to describe the total pharmacologic environ-
ment of patient care, both parts of item 11 were used to
compute total drug mentions and to describe specific
drugs prescribed in the presence of a specific diagnosis.
As the data with the highest frequencies were tabulated,
it became apparent that what emerged were chiefly the
drugs that produced the appropriate therapeutic effects
for the principal diagnosis under study. That is, medica-
tions ordered most frequently for hypertensive patients
were antihypertensive drugs or diuretics, those for dia-
betic patients were anti-diabetics, and so forth. In some
tables drugs were listed that are used for conditions
often concomitant with the principal diagnosis of inter-
est, such as cardiovascular drugs with diabetes mellitus
and osteoarthritis. In other cases the aggregation of all
available drug data provided information about pre-
ventive care during illness visits. Noteworthy in this
respect was the provision of vitamin B-12 to patients
with hypertension and the administration of influenza
virus vaccine to at-risk patients with hypertension and
ischemic heart disease. This is not to say, however, that
this is the only appropriate analytic method. The two-
part structure of the medication therapy item has the
flexibility of serving different research needs.
Increasing age was a significant factor in the utiliza-
tion of drugs with many of the diagnoses discussed in
this report. In fact, regardless of diagnosis and on the
average, drug mention rates increased with each ad-
vancing age group beginning with age group 15–24
years (figure 3). Similarly, proportions of visits that
included one or more drugs increased as did the average
number per drug visits However, because these rates
were calculated from data in both parts of item 11, it
could be argued that medication for concomitant condi-



















Under 15-24 25–44 45-64 65 and
15 over
Age in years
Figure 3. Drug mention rates per visit for all-listed druga and principal
medication by age of patient United Ststes, 1980
caused the rise in the rate (that is, elderly patients were
given more drugs because they had more problems).
Therefore, rates based on only part 11a (medication for
the principal diagnosis) were calculated and are also
plotted in figure 3. As expected, rates for the principal
medication were lower than those for all-listed (parts
11a and 11h) drugs, but both curves exhibit a similar
pattern of increase, suggesting that rising rates were not
necessarily a function of drug use for conditions other
than the principal diagnosis. Similar dual curves were
plotted for diabetes mellitus, essential hypertension,
and ischemic heart disease (figure 4). Patients visiting
with these three diagnoses tended to have interrelated
concomitant conditions for which additional therapeutic
classes of medication were ordered. For each diagnosis
the two curves increase with increasing age groups,
demonstrating that given one of these conditions, as
patients age increases they are increasingly likely to
have drugs prescribed for that condition.
It has been reported that no statistically significant
differences were found between the drug rates of female
and male patients in the 1980 NAMCS when data for
all diagnoses were examined.s Of the 18 diagnoses in
this report, the drug mention rate for female patients was
higher than that of male patients for five diagnoses:
obesity, hypertension, bronchitis, allergic rhinitis, and
intervertebral disc disorder. Although no drug mention
rates among the groups in this report were higher for male
patients, there are other diagnoses where this may occur.
NAMCS drug data reflect physicians’ choices




Under 45 45–64 65 and
over
Disbetes mellitus
Disgnosis st?d sge in years
/ “’’””-
I I I 1 I I
Under 45 45-64 65 and Under 45 45–64 65 and
over over
Essential hypertension Ischemic heart disease
Figure 4. Drug mention rates per visit for diabetes mellitus, essential hypertension, and ischemic heart disease by all-listed drugs and principal medication
and age of pstient United States, 1980
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,
products. In some parts of this report selections from
available drugs were so diverse that it was not possible
to list any one with good statistical reliability. In others,
a limited number of individual drugs described almost
the entire range of drug mentions. It is not known whether
this was due to the number of drugs available in the
pharmaceutical market, to the number of acceptable
and approved generic drugs developed to treat a dis-
ease, or to physician preference for a particular brand
name drug. NAMCS data indicate that physicians were
most likely to order brand name drugs, since 71 percent
of the drugs used were entered by manufacturer’s product
name. But what influenced a physician to select one
brand of drug rather than an equivalent one produced by
another manufacturer cannot be inferred from these
data.
Finally, this report reflects drug utilization for the
year 1980. These statistics should not be generalized to
other time periods because pharmacology is an evolving
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Appendix L Technical notes
@
This report is based on data collected during 1980
in the National Ambulatory Medical Care Survey
(NAMCS), an annual sample survey of office-based
physicians conducted by the Division of Health Care
Statistics of the National Center for Health Statistics
(NCHS).
Statistical design
Scope of the survey
The target population of NAMCS encompasses
oflice visits made within the conterminous United States
by ambulatory patients to nonfederally employed physi-
cians who are principally engaged in office-based patient
care practice, but not in the specialties of anesthesi-
ology, pathology, or radiology. Telephone contacts and
nonofflce visits are excluded.
Sample design
The NAMCS utilizes a multistage probability de-
sign that involves probability samples of primary sam-
pling units (PSU’S), physician practices within PSU’S,
and patient visits within physician practices.
The first-stage sample of 87 PSU’S was selected by
the National Opinion Research Center of the Univer-
sity of Chicago, the organization responsible for
NAMCS field and data processing operations under
contract to NCHS. A PSU is a county, a group of
adjacent counties, or a standard metropolitan statistical
area (SMSA). A modified probability-proportional-to-
size procedure using separate sampling frames for
SMSA’S and for nonrnetropolitan counties was used to
select the sample PSU’S. After sorting and stratifying
by size, region, and demographic characteristics of the
PSU’S, each frame was divided into sequential zones of
1 million residents, then a random number was drawn to
determine which PSU came into the sample from each
zone.
The second stage of the survey consisted of a prob-
ability sample of practicing physicians, selected from
the master files maintained by the American Medical
Association (AMA) and the American Osteopathic
Association (AOA)asofDecember31, 1979, who met
the following criteria:
● OffIce based, as defined by AMA and AOA.
● Principally engaged in patient care activities.
● Nonfederally employed.
● Not in the specialties of anesthesiology, pathology,
clinical pathology, forensic pathology, radiology,
diagnostic radiology, pediatric radiology, or thera-
peutic radiology.
The 1980 NAMCS physician universe included 217,500
doctors of medicine and 10,058 doctors of osteopathy
(see table I).
Within each PSU, all eligible physicians were ar-
ranged by nine specialty groups: general and family
medicine, internal medicine, pediatrics, other medical
specialties, general surgery, obstetrics and gynecology,
other surgical specialties, psychiatry, and all other spe-
cialties. Then, within each PSU, a systematic random
sample of physicians was selected so that the overall
probability of selecting any physician in the United
States was approximately constant.
During 1980 the NAMCS physician sample in-
cluded 2,959 physicians. Sample physicians were
screened at the time of the survey to insure that they met
the aforementioned criteri~ 611 physicians did not
meet all the criteria and were, therefore, ruled out of
scope (ineligible) for the study. The most common reasons
for being out of scope were that the physician was re-
tired; deceased or employed in teaching, research, or
administration. Of the 2,348 in-scope (eligible) physi-
cians, 1,869 (79.6 percent) participated in the study.
The physician sample size and response data by physi-
cian specialty are shown in table I.
The final stage was the selection of patient visits
within the annual practices of the sample physicians.
This stage involved two steps. First, the total physician
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Table 1. Distribution of physicians in the 1980 National Ambulato~ Medical Care Survey universel and sample and response rates by physician specialty
Physician specialty
All specialties . . . . . . . . . . . . . . . .
Genera land family practice . . . .
Medical specialties . . . . . . . . . . . . . .
Internal medicine......,.,.,.,., .
Pediatrics . . . . . . . . . . . . . . . . . . . . . .
Other medical specialties . . . . . . . .
Surgical specialties . . . . . . . . . . . . .
General surgery . . . . . . . . . . . . . . . .
Obstetrics and gynecology.....,..
Other surgical specialties ..,.....
Other specialties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Psychiat~ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .




Net total Non respondents Respondents
Response
total stop e rate
Number Percent
-—
227,558 2,959 611 2,348 479 1,869 79.6
53,147 676 155 521 133 388 74.5
66,692 864 172 692 138 554 80.1
35,198 458 92 366 85 261 76.8
16,043 204 46 158 19 139 88.0
15,450 202 34 168 34 134 79.8
77,625 1,002 131 871 164 707 81.2
21,486 269 39 230 60 170 73.9
18,246 247 36 211 27 184 87,2
37,893 486 56 430 77 353 82.1
30,094 417 153 264 44 220 83.3
16,662 223 55 168 22 146 86.9
13,432 194 98 96 22 74 77.1
1 ,“cludes d~~tors Of medicine and doctors Of ostewath~.
sample was divided into 52 random subsarnples of ap-
proximately equal size, and each subsample was ran-
domly assigned to 1 of the52 weeks in the survey year.
Of the participating physicians, 249 saw no patients
during their assigned reporting period because of vaca-
tions, illnesses, or other reasons for being temporarily
out of ofllce-based practice. Second, a systematic random
sample of visits was selected by the physician during the
assigned week. The sampling rate varied for this final
step from a 100-percent sample for very small practices
to a 20-percent sample for very large practices. The
method by which the sampling rate was determined is
described later in this appendix and in the Induction
Interview Form in appendix III. During 1980,46,081
usable Patient Record Forms were completed by physi-
cians participating in NAMCS.
Data collection and processing
Field procedures
Both mail and telephone contacts were used to en-
list sample physicians for NAMCS. Introductory Let-
ters from the Director of NCHS (see appendix III) were
sent to physicians first. When appropriate, a letter from
the physician’s specialty organization endorsing the
survey and urging participation was enclosed with the
NCHS letter. Approximately 2 weeks prior to the physi-
cian’s assigned reporting period, a field representative
telephoned the physician to explain briefly the study
and to arrange an appointment for a personal interview.
Physicians who did not respond initially were usually
recontacted via telephone or special explanatory letter
and requested to reconsider participation in the study.
During the personal interview the field representa-
tive determined the physician’s eligibility for the study,
obtained the cooperation of the physician, delivered
survey materials with verbal and printed instructions,
and assigned a predetermined Monday-Sunday report-
ing period. A short induction interview concerning basic
practice characteristics, such as type of practice and
expected number of oflice visits, was conducted. IOfflce
staff who were to assist with data collection were invited
to attend the instructional session or were offered sep-
arate instructional sessions.
Before the beginning and again during the week as-
signed for data collection, the field representative tele-
phoned the sample physician to answer questions that
might have arisen and to insure that survey procedures
were going smoothly. At the end of the reporting week,
the participating physician mailed the completed suryey
materials to the field representative, who edited the
forms for completeness before transmitting them for
central data processing. At this stage, problems of mis-
sing or incomplete data were resolved by telephone
followup by the field representative to the sample :physi-
cian; if no problems were found, field procedures were
considered complete regarding the sample physician’s
participation in NAMCS.
Data collection
The actual data collection for NAMCS was per-
formed by the physician, assisted by ofllce staff when
possible. Two data collection forms were employed by
the physician: the Patient Log and the Patient Record
(see appendix III). The Patient Log, a sequential listing
of patients seen in the physician’s office during the
assigned reporting week, served as the sampling frame
to indicate the ofl-lce visits for which data were to be
recorded. A perforation between the patient’s name and
patient visit information permitted the physician to de-
tach and retain the listing of patients, thus protecting the
confidentiality of the physician’s patients.
Based on the physician’s estimate of the expected
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number of office visits and expected number of days in
practice, each physician was assigned a patient sampling
rate. The patient sampling rates were designed so that
about 30 Patient Record Forms would be completed by
each physician during the assigned reporting week.
Physicians expecting 10 or fewer visits each day re-
corded data for all visits, those expecting more than 10
visits per day recorded data for every second, third, or
fifth visit, based on the predetermined sampling interval.
These patient sampling procedures minimized the phy-
sician’s data collection workload and maintained ap-
proximately equal reporting levels among sample phy-
sicians regardless of practice size. For physicians re-
cording data for every second, third, or fifth patient visit,
a random start was provided on the first page of the
Patient Log so that predesignated sample visits recorded
on each succeeding page of the Patient Log provided a
systematic random sample of patient visits during the
reporting period.
Data processing
In addition to followups for missing and inconsist-
ent data made by the field staff, numerous clerical edits
were performed on data received for central data proces-
sing. These manual procedures proved quite efilcient,
reducing item nonresponse rates to 2 percent or less for
most data items.
Information contained in item 6 (Patient’s com-
plaint(s), symptom(s), or other reason(s) for this visit)
of the Patient Record was coded according to “A reason
for visit classl~cation for a7nbulato7y care” @7C].~z
Diagnostic information (item 9 of the Patient Record)
was coded according to the Intematz”onal Classl@ation
ofDiseases, 9th Revision, ClinicalModl~cation (ICD–
9–CM).1 A maximum of three entries were coded from
each of these items. Prior to coding, Patient Record
Forms were grouped into batches with approximately
650 Patient Record Forms per batch. Quality control
for the medical coding operation involved a two-way 5-
percent independent verification procedure. Error rates
were defined as the number of incorrectly coded entries
divided by the total number of coded entries. The esti-
mated error rates for the medical coding operation were
1.9 percent for item 6 and 2.8 percent for item 9. An
additional dependent procedure was used to review and
adjudicate all records in batches with excessive error
rates. This procedure IWher reduced the estimated
error rates to 1.8 percent for item 6 and 2.5 percent for
item 9.
The NAMCS medication data (item 11 of the Pa-
tient Record) was classified and coded according to a
scheme developed at NCHS based on the American
Society of Hospital Pharmacists’ Drug Product Infor-
mation File. Detailed descriptions of the development
of the new drug coding scheme and of the NAMCS
NOTE: A list of references follows the text.
drug data processing procedures are contained in Vital
andHealth Stat’ish”cs,Series 2, No. 90.6A twsway 100-
percent independent veritlcation procedure was used to
control the medication coding operation. All Patient
Record Forms with differences between drug coders or
with illegible drug entries were reviewed and adjudi-
cated at NCHS.
Information from the Induction Interview and Pa-
tient Record Forms was keypunched with 100 percent
verification and converted to computer tape. At this
point, extensive computer consistency and edit checks
were performed to insure complete and accurate data.
Incomplete items were imputed by assigning a value
from a randomly selected Patient Record Form with
similar characteristics; patient sex and age, physician
specialty, and broad diagnostic categories were used as
the basis for these imputations.
Estimation procedures
Statistics from the 1980 NAMCS were derived by a
multistage estimation procedure that produces essen-
tially unbiased national estimates and has three basic
components: (1) inflation by reciprocals of the prob-
abilities of selection, (2) adjustment for nonresponse,
and (3) a ratio adjustment to fixed totals. Each com-
ponent is briefly described in this section.
Inflation by reciprocals of the
probabilities of selection
Because the survey utilized athree-stage sample de-
sign, three probabilities of selection existed: (1) the
probability of selecting the PSU, (2) the probability of
selecting the physician within the PSU, and (3) the
probability of selecting a patient visit within the physi-
cian’s practice. The last probability was defined as the
exact number of ofllce visits during the physician’s
assigned reporting week divided by the number of Pa-
tient Record Forms completed. All weekly estimates
were inflated by a factor of 52 to derive annual estimates.
Adjustment for nonresponse
Estimates for NAMCS data were adjusted to ac-
count for sample physicians who did not participate in
the study. This adjustment was calculated to minimize
the impact of response on final estimates by imputing to
nonresponding physicians the practice characteristics
of similar responding physicians. For this purpose, phy-
sicians were judged similar if they had the same specialty
designation and practiced in the same PSU.
Ratio adjustment
A poststratilcation adjustment was made within
each of nine physician specialty groups. The ratio ad-
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justment was a multiplication factor that had as its
numerator the number of physicians in the universe in
each physician specialty group and as its denominator
the estimated number of physicians in that particular
specialty group. The numerator was based on figures
obtained from the AMA and AOA master files, and the
denominator was based on data from the sample.
Reliability of estimates
As in any survey, results are subject to both sam-
pling and nonsampling errors. Nonsampling errors in-
clude reporting and processing errors, as well as biases
due to nonresponse or incomplete response. The magni-
tude of the nonsampling errors cannot be computed;
however, these errors were kept to a minimum by survey
procedures. To eliminate ambiguities and encourage
uniformity of reporting, careful attention was given to
the phrasing of the questions, terms, and definitions,
and, in addition, extensive pretesting was performed.
The steps taken to reduce bias in the data are discussed
in the sections on field procedures and data collection.
Quality control procedures and consistency and edit
checks discussed in the data processing section reduced
errors in data coding and processing; however, because
survey results are subject to sampling and nonsampling
errors, the total error will be larger than the error due to
sampling variability alone.
Because the statistics presented in this report are
based on a sample, they differ somewhat from the figures
that would be obtained had a complete census been
taken using the same forms, definitions, instructions,
and procedures. However, the probability design of
NAMCS permits the calculation of sampling errors.
The standard error is primarily a measure of sampling
variability that occurs by chance because only a sample
rather than the entire population is surveyed. The stand-
ard error, as calculated in this report, also reflects part of
the variation that arises in the measurement process. It
does not include estimates of any systematic biases that
may be in the data. The chances are about 68 out of 100
that an estimate from the sample would differ from a
complete census by less than the standard error. The
chances are about 95 out of 100 that the difference
would be less than twice the standard error, and about
99 out of 100 that it would be less than 2% times as
large.
The relative standard error of an estimate is ob-
tained by dividing the standard error by the estimate
itself and is expressed as a percent of the estimate. For
this report, an asterisk (*) precedes any estimate with
more than a 30-percent relative standard error.
Estimates of sampling variability were calculated
using the method of half-sample replication. This method
yields overall variability through observation of varia-
bility among random subsamples of the total sample. A
description of the development and evaluation of the
replication technique for error estimation has been pub-
lished. 1311Approximate relative standard errors for ag-
gregate estimates are presented in figures I and II. To
derive error estimates that would be applicable to a wide
variety of statistics and could be prepared at moderate
cost, several approximations were required. As a result,
the relative standard errors shown in figures I and II
should be interpreted as approximate rather than exact
for any specific estimate. Directions for determining
approximate relative standard errors follow.
Estimates of aggregates
Approximate relative standard errors (in percent)
for aggregate statistics are presented in figures I and II.
Figure I presents approximate relative standard errors
for estimates of ofi-lce visits, while figure II presents
approximate relative standard errors for estimates of
drug mentions. (Figure I should also be used to obtain
the relative standard error of a speczfic drug mention
such as Dyazide: Figure II should also be used to obtain
the relative standard error of a group of drug mentions
such as all drugs prescribed for hypertension.) In each
figure, curve A represents the relative standard errors
appropriate for estimates based on all physician special-
ties, and curve 1? representa relative standard errors
appropriate for estimates based on an individual physi-
cian specialty.
Alternatively, relative standard error (RSIE) for
aggregate estimates maybe calculated directly using the
following formulas, where x is the aggregate of interest
in thousands. For visit estimates (or for mentions of a
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Estimates of percents
Approximate relative standard errors (in percent)
for estimates of percents maybe calculated from figures





















































A 2 3 456789A 2 3 456789A 2 3 456789A 2 3 456789A
100 1,000 10,000 100,000 1,000,000
Size of estimate (in thousands)
Examp/e of use ofchati.’An estimete of 20 million office visits to general surgeons (read from scale at bottom of chart) has a relative standard error of 7.9 percent (read from curve B on acaleat Ieftofchati)
or a standard error of 1,580,000 office visita (7.9 percent of 20 million office visits).
Figure 1. Approximate relative standard errora for estimated numbers of office visits based on all physician specialties (A) and individual specialties (B), 1980
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A 2 3 456789A 2 3 456789A 2 3 456789A 2 3 456789A
100 1,000 10,000 100,000 1,000,000
siZc3 Of estimate (in thousands)
ExamP/e of use of chart: An estimata of 60 million drug mentions to general practitioners (read on scale at bottom of chart) has a relative standard error of 9.7 percent (read from cume B On scale at left
of chart) or a standard error of 5,820.000 drug mentions (9.7 percent of 60 million drug mentions).
Figure Il. Approximate relative standard errors for estimated numbers of drug mentions based on all physician specialties (A) and individual specialties (B), 1980
National Ambulatory Medical Care Survey
I and II. The relative standard error of the numerator
and denominator of the percent is obtained from the
appropriate curve; each of the relative standard errors is
squared; the resulting value for the denominator is sub-
tracted from the resulting value for the numeratoq and
the square root is extracted. This approximation is valid
if the relative standard error of the denominator is less
than 0.05 percent or if the relative standard errors of the
numerator and denominator are both less than 0.10
percent.
Alternatively, relative standard errors for percents
may be calculated directly using the following formulas,
wherep is the percent of interest and x is the base of the
percent in thousands. For visit percents (or percents of a
specific drug) based on all physician specialties,
RSE(p) =
d
36.36433 “(1 –p) .1000
p“x
For visit percents (or percents of a specific drug) based
on an individual physician specialty,




71.26431 o(1 –P). ~ooo
p“x
For m-ouped drug mention percents based on an indi-
vidu~l physician <pecialty, -
Estimates of rates where the numerator
is not a subclass of the denominator
Approximate relative standard errors
100.0
for rates in
which-he denominator is the total United States popu-
lation or one or more of the age-sex-race groups of the
total population are equivalent to the relative standard




The relative standard errors shown in this appendix
are not directly applicable to differences between two
sample estimates. The standard error of a difference is
approximately the square root of the sum of squares of
each standard error considered separately. This for-
mula represents the standard error quite accurately for
the difference between separate and uncorrelated char-
acteristics, although it is only a rough approximation in
most other cases.
Tests of significance
In this repo~ the determination of statistical in-
ference is based on the t-test with a critical value of 1.96
(0.05 level of significance). Terms relating to differ-
ences, such as “higher” and “less,” indicate that the
differences are statistically significant. Terms such as
“similar” or “no difference” mean that no statistical
significance exists between the estimates being com-
pared. A lack of comment regarding the difference be-
tween any two estimates does not mean that the differ-
ence was tested and found to be not significant.
Population figures and rate computation
The population figures used in computing annual
visit rates are presented in table II. The figures are based
on provisional Bureau of the Census estimates of the
civilian noninstitutionalized population of the United
States as of July 1, 1980. Because NAMCS includes
data for only the conterminous United States, the or-
iginal population estimates were modified to account
for the exclusion of Alaska and Hawaii from the study.
For this reason, the population estimates should not be
considered oi%cial and are presented here solely to pro-
vide denominators for rate computations.
Rounding of numbers
Estimates presented in this report have been rounded
to the nearest thousand. For this reason detailed figures
within tables do not always add to totals. Rates and
percents were calculated on the basis of the original,
unrounded figures and may not necessarily agree pre~
cisely with percents calculated from rounded data.
Systematic bias
No formal attempt was undertaken to determine or
measure systematic bias in the NAMCS data. But it
should be noted that there are several factors affecting
the data which indicate that these data underrepresent
the total number of office visits. Two of these factors are
briefly discussed:
● Physicians who participated in NAMCS did a thor-
ough and conscientious job in keeping the Patient
Log however, post survey interviews with partici-
pating physicians indicate that a small number of
patient visits may have been accidentally omitted
from the Patient Log although this number is quite
small, such omissions would result in an undercov-
erage of oi%ce visits. The same post survey inter-
views indicate that the inclusion of patient visits that
did not actually occur was infrequent and would
have a negligible effect on survey estimates.
● As previously stated, the universe for the 1980
NAMCS included all non-Federal, ofilce-based,
patient-care physicians in the AMA and AOA mas-
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Table Il. Estimates of the civilian noninstitutionalized population of the United Statesl used in computing annual visit rates in this reporl by age, race, sex,
geographic region, and metropolitan and nonmetropolitan area: July 1, 1980
Age
Selected characteristic All ages Less
than 15
15-24 25-44 45-64 65 years
years




Metropolitan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .,

















































































. . . . . .
. . . . . .
. . . . . .
. . .
. . . . .
. . . . .
1 Excludes Alaska and Hawaii,
NOTE: Figures may not add to totals dua to rounding.
ter files. The NAMCS was designed to provide
statistically unbiased estimates of office visits to
this designated population. Not included in the uni-
verse were physicians classified in such categories
as federally employed, hospital-based, research,
teaching, administration, or other nonpatient care
activity. Consequently, any ambulatory patient
visits to these physicians in an office setting are not
included in NAMC S estimates. In an attempt to
measure the number of office visits to physicians not
in the NAMCS universe, a NAMCS Complement
Survey was conducted in 1980. This study involved
a sample of approximately 2,000 physicians selected
from among the 226,000 physicians in the AMA
and AOA master files who were not eligible (in
scope) for the 1980 NAMCS. Details of the Com-
plement Survey methodology and results are forth-
coming. Preliminary results indicate that about 17
percent of the Complement Survey universe saw
some ambulatory patients in an office setting. An
estimated 69 million ofllce visits were made to these
physicians in 1980. This indicates that the total
number of oflice visits to all physicians during 1980
was about 645 million (69 million plus 576 million).
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Appendix 11. Definition of
Terms
Terms relating to the survey
0j71ce.-Premises identified by physicians as loca-
tion for their ambulatory practices. The responsibility
over time for patient care and professional services
rendered there generally resides with the individual
physician rather than with any institution.
Ambulatory patient.—An individual seeking per-
sonal health services who is neither bedridden nor cur-
rently admitted to any health care institution on the
premises.
Physician. —Classified as either:
● In scope.—All duly licensed doctors of medicine or
doctors of osteopathy currently in practice who
spend some time caring for ambulatory patients at
an office location.
● Outofscope. —Those physicians who treat patients
only indirectly, including physicians in the special-
ties of anesthesiology, pathology, forensic path-
ology, radiology, therapeutic radiology, and diag-





Physicians who are federally employed, includ-
ing those physicians in military service.
Physicians who treat patients only in an insti-
tutional setting for example, patients in nursing
homes and hospitals.
Physicians employed full time in industry or by
an institution and having no private practice; for
example, physicians who work for the Veterans’
Administration or the Ford Motor Company.
Physicians who spend no time seeing ambula-
to~ patients; for example, physicians-who only
teach, are engaged in research, or are retired.
Patients. —Classified as eithe~
● In scope.—All patients seen by the physician or a
staff member in the office of the physician.
● Out of scope.—Patients seen by the physician in a
hospital, nursing home, or other extended care insti-
tution, or in the patient’s home. (Note: If the phy-
sician has a private ofilce, meeting the definition of
“office,” located in a hospital, the ambulatory pa-
tients seen there are considered in scope.) The fol-





Patients seen by the physician in an institution,
including outpatient clinics ofhospitals, for whom
the institution has primary responsibility over
time.
Patients who contact and receive advice from
the physician via telephone.
Patients who come to the oi%ce only to leave a
specimen, to pickup insurance forms, or to pay
a bill.
Patients who come to the ofilce only to pick UP
medications previously prescribed by the ph~-
sician.
Visit.—A direct, personal exchange between an
ambulatory patient and a physician or a staff member
for the purpose of seeking care and rendering health
services.
Physicianspecialty. -l?rincipal specialty, including
general practice, as designated by the physician at the
time of the survey. Those physicians for whom a spe-
cialty was not obtained were assigned the principal
specialty recorded in the physician master files main-
tained by the American Medical Association or the
American Osteopathic Association.
Region ofpractice location.—The four geographic
regions, excluding Alaska and Hawaii, that correspond
to those used by the U.S. Bureau of the Census:
Region States included
Northeaat . . . . . . Connecticut, Maine, Massachusetts, New
Hampshire, New Jersey, New York, Penn-
sylvania, Rhode Island, and Vermont
North Central . . Illinois, Indiana, Iowa, Kansas, Michigan,
Minnesota, Missouri, Nebraska, North Da-
kota, Ohio, South Dakota, and Wisconsin
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Reg/On— COn. States )ncluded— Con Rican. Cuban. Central or South American. or other
South ... Alabama, Arkansas, Delaware, District of
Columhm, Flor!da, Georg!a, Kentucky, Lou-
[stana, Maryland, Mlsslssippl, North Caro-
I!na, Oklahoma, South Carolina, Tennessee,
Texas, Virginia, and West V!rglnia
West. . . . Arizona, California, Colorado, Idaho, Mon-
tana, Nevada, New Mexico, Oregon, Utah,
Washington, and Wyom!ng
Metropolitan status ofpractice location. —A phy-
sician’s practice is classified by its location in a metro-
politan or nonrnetropolitan area. Metropolitan areas
are standard metropolitan statistical areas (SMSA’S) as
defined by the U. S. Office of Management and Budget.
The definition of an individual SMSA involves two
considerations: first, a city or cities of specified popula-
tion that constitute the central city and identify the
county in which it is located as the central county;
second, economic and social relationships with “con-
tiguous” counties that are metropolitan in character so
that the periphery of the specific metropolitan area may
be determined. SMSA’S may cross State lines. In New
England, SMSA’S consist of cities and towns rather
than counties.
Terms relating to the
Patient Record Form
Age. —The age calculated from date of birth was the
age at last birthday on the date of visit.
Color or race. —White, Black, Asian/Pacific Is-
lander, or American Indian/Alaskan Native. Physicians
were instructed to mark the category they judged to be
the most appropriate for each patient based on observa-
tion or prior knowledge. The following definitions were
provided to the physician:
White. —A person having origins in any of the or-
iginal peoples of Europe, North Africa, or the Middle
East.
B[ack. —A person having origins in any of the black
racial groups of Africa.
Asian/Pacz~c Islander. —A person having origins
in any of the original peoples of the Far East, South-
east Asia, the Indian subcontinent, or the Pacific
Islands. This area includes, for example, China,
India, Japan, “Korea, the Philippine Islands, and
Samoa.
Amen-can Indian/A laskan Native.—A person hav-
ing origins in any of the original peoples of North
America and who maintains cultural identification
through tribal affiliation or community recognition.
Ethnicity. —Category judged by the physician to be
the most appropriate. The following definitions were
provided:
@ Hispanic origin. —A person of Mexican, Puerto
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Spanish culture or origin, regardless of ra~e.
Not Hispanic. —Any person not of Hispanic origin.
Patient’s complaintisj, sym~tom(sl other reason(s)
for this visit (;npatie;t ;w; words)~–The patien~’~
principal problem, complaint, symptom, or other
reason for this visit as expressed by the patient.
Physicians were instructed to record key words or
phrases verbatim to the extent possible, listing that
problem first which, in the physician’s judgment,
was most responsible for the patient’s visit.
Major reason for this visit.—The one major reason
(selected from the following list) for the patient’s visit as
judged by the physician:
● Acute problem. —A visit primarily for a condition
or illness having a relatively sudden or recent onset
(within 3 months of the visit).
● Chronic problem, routine. —A visit primarily to
receive regular care or examination for a preexisting
chronic condition or illness (onset of condition was
3 months or more before the visit).
o Chronic problem, jlareup. —A visit primarily to
receive care for a sudden exacerbation of a preexist-
ing chronic condition or illness.
● Post surge~/post irzj”ury.—A visit primarily for
followup care of injuries or for care required follow-
ing surgery; for example, removal of sutures or cast.
● Non-illness care (routine prenatal, general exam,
well-baby, etc.).—General health maintenance ex-
aminations and routine periodic examinations .of
presumably healthy persons, both children and
adults, including prenatal and postnatal care, an-
nual physicals, well-child examinations, and insur-
ance examinations.
Diagnostic services this visit. —Physicians were
instructed to check any of the following services that






Limited histo~/exam.—History or physical ex-
amination limited to a specific body site or system
or concerned primarily with the patie’nt’s chief com-
plaink for example, pelvic examination or eye ex-
amination.
General history/exam. —History or physical ex-
amination of a comprehensive nature, including all
or most body systems.
Pap test. —Papanicolaou test.
Clinical lab test. —One or more laboratory proce-
dures or tests, including examination of blood, urine,
sputum, smears, exudates, transudates, feces, and
gastric content, and including chemistry, serology,
bacteriology, and pregnancy test excludes Pap
test.
X-raj~.—Any single or multiple X-ray examination




Vision test. —Visual acuity test.
l?rzdoscopy.-Exarnination of the interior of any
body cavity except ear, nose, and throat by means
of an endoscope.
Mental statusexan2.-Any formal, clinical evalua-
tion designed to assess the mental or emotional
status of the patient.
Othex—All other diagnostic services ordered or pro-
vided that are not included in the preceding categories.
Principal diagnosis. -The physician’s diagnosis of
the patient’s principal problem, complaint, or symptom.
In the event of multiple diagnoses, the physician was
instructed to list them in order of decreasing importance.
The term “principal” refers to the first-listed diagnosis.
The diagnosis represents the physician’s best judgment
at the time of the visit and maybe tentative, provisional,
or definitive.
Other significant current diagnoses.—The diag-
nosis of any other condition known to exist for the
patient at the time of the visit. Other diagnoses mayor
may not be related to the patient’s reason for visit.
Have you seen patient before?—” Seen before”
means provided care for at any time in the past. Item
10b refers to the patient’s current episode of illness.
Medication therapythisvisit.—The physician was
instructed to list, using brand or generic names, all
medications, including drugs, vitamins, hormones, oint-
ments, and suppositories ordered, injected, administered,
or provided this visit including prescription and nonpre-
scription drugs, vaccinations, immunization, and de-
sensitization agents. Also included are drugs and medi-
cations ordered or provided prior to the visit that the
physician instructed or expected the patient to continue
taking. Medications for the principal diagnosis are listed
in item 11a; all other drugs are listed in item 11b.
Non~medication therapy.—Physicians were in-
structed to check any of the following services that were
ordered or provided during the current visit:
● Physiotherapy.—Any form of physical therapy or-
dered or provided, including any treatment using
heat, light, sound, or physical pressure or move-
men~ for example, ultrasonic, ultraviolet, infrared,
whirlpool, diathermy, cold, and manipulative
therapy.
● 0~7ce surgery.—Any surgical procedure performed
in the ofilce this visit, including suture of wounds,
reduction of fractures, application or removal of
casts, incision and draining of abscesses, applica-
tion of supportive materials for fi-actures and sprains,







Familyplanning.—Services, counseling, or advice
that might enable patients to determine the number
and spacing of their children, including both contra-
ception and infertility services.
Psychotherapy/therapeutic listening.—All treat-
ments designed to produce a mental or emotional
response through suggestion, persuasion, reeduca-
tion, reassurance, or support, including psycholog-
ical counseling, hypnosis, psychoanalysis, and
transactional therapy.
Diet counseling.—Instructions, recommendations,
or advice regarding diet or dietary habits.
Family/socialcounseling. —Advice regarding prob-
lems of family relationships, including marital or
parent-child problems, or social problems, includ-
ing economic, educational, occupational, legal, or
social adjustment dit%culties.
Medical counseling.—lkstructions and recom-
mendations regarding any health problem, includ-
ing advice or counsel about a change of habit or
behavior. Physicians were instructed to check this
category only if medical counseling was a signif-
icant part of the treatment. Family planning, diet
counseling, and family/social counseling are ex-
cluded.
Othez —Treatments or non-medication therapies
ordered or provided that are not listed or included in
the preceding categories.
Waspatient referredfor thisvisitby anotherphysi-
cian?—Referrals are any visits that are made at the
advice or direction of a physician other than the one
being visited. The interest is in referrals for the current
visit and not in referrals for any prior visit.
Disposition this visit. —Eight categories are pro-
vided to describe the physician’s disposition of the case.
The physician was instructed to check as many of the
categories as appIy:
Nofollowupplanned—No return visitor telephone
contact was scheduled for the patient’s problem.
Return at specijied time. —Patient was told to
schedule an appointment or was instructed to return
at a particular time.
Return l~neede~ P.RN.—No future appointment
was made, but the patient was instructed to make an
appointment with the physician if the patient con-
sidered it necessary.
Telephone follow-up planned. —Patient was in-
structed to telephone the physician on a particular
day to report either on progress, or if the need arose.
Refeiredto otherphysician.—Patientwas instructed
to consult or seek care from another physician. The
patient may or may not return to this physician at a
later date.
Returned to referringphysician. —Patient was in-
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strutted to consult again with the referring physi-
cian.
. Admit to hospital. —Patient was instructed that
further care or treatment would be provided in a
hospital. No further office visits were expected prior
to hospital admission.
● Other. —Any other disposition of the case not in-
cluded in the preceding categories.
Duration of this visit. —Time the physician spent
with the patient, not including time the patient spent
waiting to see the physician, time the patient spent re-
ceiving care from someone other than the physician
without the presence of the physician, and time the phy-
sician spent in reviewing such things as records and test
results. If the patient was provided care by a member of
the physician’s staff but did not seethe physician during
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of its continuingprogramto provideinformationon








The purposeof thissurveyis to collectinformation
aboutambulatorypatients,theirproblems,and the









Sincepracticingphysiciansare the only reliablesource
of this information,we need your assistancein the
WS. As one of the physiciansselectedin our national
sample,yourparticipationis essentialto the success
of the survey. Of course,all informationthatyou









Many organizationsand leadersin the medicalprofession
haveexpressedtheirsupportfor this survey,including
thoseshownto the left. In particular,your own spe-
cialtysocietyhas reviewedthe NAMCSprogramand supports






Withina few days,a surveyrepresentativewill telephone
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PATlENT LOG
~ “-””--- “- 1 ,
PATlENT RECORD
NATIONAL AMBULATORY MEDICAL CARE SURVEY
As each patient arrives, record nama and
time of visit on the log below. For the
pstinnt entamd on Iina *, also cam.
plete the patient record to the right.
I
PATlENT’S NAME TIME OFVISIT
1. DATE OF VISIT
&
- =
!’] 5 I INON. ILLNESS CARE [ROUTINE











B. DIAGNOSTIC SERVICES THIS VISIT
[Check all orden?d or provided!
I ❑ NONE 8 H EKG
2 ❑ LIMITED HK.TORY/EXAM. 9 ❑ V1510N TEST.
3 ❑ GENERAL HISTfJRYIEXAM. IO ❑ ENOOSCOPY
4 ❑ PAP TEST ,, ❑ M:::fl,LSTATUS




11, MEDICATION THERAPY THIS VISIT
am PATIENT’S COMPLAINT(S), SYMPTOM(S), OR OTHER




,. PRINCIPAL DIAGNOSISIPROBLEM ASSOCIATED WITH ITEM 60
b. OTHER SIGNIFICANT CURRENT DIAGNOSES
[ Using brand or generic names, recoti all new and continued medications otiered, injected, administered, or otherwise
provided at this visr. Include immunizing and desensitizing agen ts]








I HNONE 6 QDIETCOUNSEL,NG
2 ❑ PHYSIOTHERAPY 7 QFAM,LY,sDciAL
a.m. COUNSELING
3 ❑ OFFICE SURGERY
4 ❑ FAPAILYPLANNING 8 ❑ MED,cALcOUNsEL,NG
5 ❑ psYcH0THE17*PY, 9 ❑ OTHER MWLIJY,
Rmord ,tem, 1-15













1 ❑ NO FOLLOW.UP PLANNED
2 ❑ RETURNAT5PECIFlED T,ME
3 ❑ RETuRN IF NEEDED. P.R.N.
a j_JTELEpHONEFOLLOW.UppMNNED
5 ❑ REFERREOTOOTHER pHYs,c,AN
6 ❑ RETURNE070 REFERRING PHYSICIAN




























2. ENTER DATES OF ASSIGNED REPORTING WEEK I__i
Q. 2, P. 2.
h
Doctor, before I begin, let me take a minute to give you a little background about
this survey.
Although ambulatory medical care accounts for nearly 90 percent of all medical care
received in the United States. there is no systematic information about the charac-
teristics and problems of peo~le who consult-physicians in their”offices.
——
ThiS kind
of information has been badly needed by medical educators and others concerned with
the medical manpower situation.
In response to increasing demands for this kind of information, the National Center
for Health Statistics, in close consultation with representatives of the medical
profession, has developed the National Ambulatory Medical Care Survey.
Your own task in the survey is simple, carefully designed, and should not take much
of your time. Essentially, it consists of your participation during a specified
7-day period. During this period, you simply check off a minimal mount of informs.
tion concerning patients that you see.
Now, before we get into the actual procedures, I have a few questions to ask about
your practice. The answers you give me will be used only for classification and *
analysis, and of course information you provide is held in strict confidence.
1. First, you are a
(ENTER SPECIALTY FROM CODE ON FACE SHEET LABEL.)”
Is that right? Yes . . . . . . . . . . .X
No. . . . (ASK A) . . ..Y
A. IF NO: What is your specialty (including general practice)?
[111
(Name of Specialty) 11-13/
The National Ambulatory Medical Care Survey is authorized by
Congress in Public Law 93-353, section 308. It is a voluntary
study and there are no penalties fcr refusing to answer any
question. All information collected is confidential and will
be used only to prepare statistical summaries. NO information




(that’s a (that’s a
/ Monday) through / - Sunday)
month date month date
you likely to see ~ ambulatory patients in your office during
Yes. . . . , .(GOTOQ. 3).
BELOW).
2. Now, doctor, this study will be concerned with the ambulatory patients you will






NO .’. . . . . (ASK A). . . . Y
IF NO: WhY is that? RECORD VERBATIM. THEN READ PARAGRAPH BELCKJ
Since it’s very important, doctor, that we include any ambulatory patients
that you do happen to see in your office during that week, I’d like to
leave the= forms with you anyway--just in case your plans change. 1’11
plan to check bacl?with your office just before (STARTING DATE) to make
sure, and I can explain them in detail then, if necessary.
GIVE DOCTOR ‘THE~ PATIENT RECORD FORMS AND GO TO Q. 9, P. 6.
8CI
-3-
3, & M what office location will you be #eet




B. FOR EACH OFFICE LOCATION ENTERED IN A, CODE YES ORNO TO “IN SCOPE.”
~ OUT OF SCOPE {No)j
Private offices Hospital emergency rooms
Free-standing clinics Hospital outpatient departments
(non-hospital based) College or university infirmaries
Groups, partnerships Industrial outpatient facilities
Kaiser, HIP, Mayo Clinic Family planning clinics
Neighborhood Health Centers Government-operated clinics
Privately operated clinics (VD, maternal & child health, etc.)
(except family planning)
IN CASE OF DOUBT, ASK: Is that (clinic/facility/institution)hospital based?
Is that (clinic/facility/institution) government
operated?
c. Is that ~ of the office locations at which you expect to see ambulatory
patients during that week?
Yes. . . . . . . . . . . X
No . . . . . . . . . . . Y
IF NO: OEZAIN ADDITIONAL OFFICE LOCATION(S), ENIER IN “A” BELOU, AND REPEAT.
A. B.









IF ALL LOCATIONS ARE OUT OF SCOPE, THANK THE DOCTOR AND LEAVE.
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-4- DECK 3
4. A. During that week (REPEAT DATES ),,how many ambulatory patients do you expect
to see in your office practice? (DO NOT coum PATIENTS SEEN A’r [OUT-OF-SCOPE
LOCATIONS] CODED IN 3-B.)
ENTER TOTAL UNDER “A” BELOW AND CIRCLE NUMBER CATEGORY N APT’Q .ROF&QITE L=
B. And during those seven days (REPEAT DATES IF NECESSARY), on how many @ do
you expect to see any ambulatory patients? COUNT EACH DAY IN WHICH DOCTOR
EXPECTS TO SEE ANY PATIENTS AT AN IN-SCOPE OFFICE LOCATION.
CIRCLE NUMBER OF DAYS IN APPROPRIATE CCLUMN UNDER “B” BELOW.
DETERMINE PROPER PATIENT LOG FORM-FROM CHART BELOW. READ ACROSS
ON “TOTAL PATIENTS” LINE UNDER “A” AND CIRCLE LETTER IN APPROPRIATE
“DAYS” COLUMN UNDER “B.”
THIS LETTER TELLS YOU WHICH OF THE FOUR PATIENT LOG FORMS (A, B, C, D)
SHOULD BE USED BY THIS DOCTOR.
LOG FORM DESCRIPTION
A--Patient Record is to be
completed for ALL
patients Iiste=n Log.
















Total ~ in practice





1- 12 PATIENTS AAAAAAA
13- 25 “ B AAAAA~
r
26- 39 “ CBAAAA7
40- 52 “ ICBBAA AA
53- 65 “ [D CB BA AA
66- 79 “ tD C B B B AA
80- 92 “ DDCBBBB
93-105 “ D D C B B B’~
106-118 “ D “D C C B By
119-131 “ DDCCBBB







198-210 “ I DDDDDDD
211+ 11 ID DDDDDD
*
In the rare instance the physician will see more than 500 patients during
his assigned reporting week, give him two D Patient Log Folios and instruct him
to complete a patient record form for only every tenth patient. Then you are
to draw an X :lhrough the ?atient Record on every other page of the two folio pads,
starting with Page 1 of,the pad. The physician then completes the Patient Log
on every page, but completes the Patient Record on every second page.
82
-5-
5. FIm LOG FOLIO WITH APPROPRIATE LETTER.AND CIRCLE LETTER, ENTER FIRST FOUR
OF THE FORM AND NUMBER OF LINES STAMPED “BEGIN ON NEXT LINE” FOR THE B-C-D




“No. Lines FOR OFFICE USE ONLY
Stamped “BEGIN Number patient record










6. HAND DOCTOR HIS FOLIO AND EXPLAIN H(XJFORMS ARE TO BE FILLED OUT. SHOW DOCTOR
INSTRUCTIONS ON THE POCKET OF FOLIO, ITEMS ~ AND 11 ON CAR@ IN POCKET
OF FOLIO AND ITEM DEFINITIONS ON THE BACK OF FOLIO, TO WHICH HE CAN REFER AFTER
YOU LEAVE.
EMPHAS12E THAT EVERY PATIENT VISIT EXCEPT ADMINISTRATIVE PURPOSE ONLY IS TO BE
RECORDED ON THE LOG FOR ENTIRE REPORTING PERIOD. FOR EXAMPLE, IF A MEDICAL
ASSISTANT GAVE THliPATIENT AN INOCULATION, OR A TECHNICIAN ADMINISTERED AN
ELECTROCARDIOGRAM AND THE PATIENllDID NUI SEE THE DOCTOR. THIS VISIT mST STILL BE
LISTED ON THE LOG.
RECORD VERBATIM BEL@l ANY CONCERN, PROBLEMS OR QUESTIONS THE DOCTOR RAISES.
7. IF DOCTOR EXPECTS TO SEE AMBULATORY PATIENTS AT FS3RETHAN ONE IN-SCOPE LOCATION
DURING ASSIGNED WEEK, TELL HIM YOU WILL DELIVER THE FORMS TO THE OTHER LOCATION(S).
ENTER THE FORM LETTER AND NUMBER(S) AND NUMBER OF LINES STAMPED “BEGIN ON NEXT
LINE” FOR THE B-C-D LOG FOR THOSE LOCATIONS BELOW, BEFORE DELIVERING FORM(S).
FOLIO No. Lines
.1
v FOR OFFICE USE ONLY:
Location Stamped “BEGIN Number Patient recor









8. Duringthe surveyweek (REPEAT EXACT DATES), will anyonebe availableto help
you in fill$agout theee records (at each IN.SCOPElocation)?
Yes . . . . (ASKA) ...1 ,51/
No . . . . . . . . . . .2
A. IF YES: Who would that be?
RECORDNAME, POSITIONAND LOCATION.
I NAMS 1 POSITION i LOCATION J
PERSONALLYBRIEF EACN PERSON LISTEDABOVE.
EMPHASIZETHAT EVERY PATIENIVISIT DURINGTHE ENTIREWEEK IS TO BE RECORDBDONTNE
LOG EXCEPT “ADMINISTRATIVE PURPOSE ONLY. ”
9. Do you have a 801opractice,or are you aamociatedwith other phy6icienmin a
partnership,in a grouppractice,or in 80UW otherway?
solo. , , . . (m TO.Q. 10) . . 1
Partnership. . (ASKA-C) . . . 2.
Group . . . ..(AC)A-C) . ..3
<--- Other (s~c~~ AND AsKA-C) , . 4
IF PARTNERSHIP,GROUP,OR OTHER:
A. 16 this a prepaidgrouppractice? Yea . . (AsK[l]) . . . 1
[1] IF YES TO A: What per cent
No . . . . . . . . . .2
of patientaare
prepaid? per cent
B. How many otherphyeicianeare
ammciated with you? NUMBER OF PHYSICIANS:
c. What are the specialtiesof the other physiciansassociatedwith y~u?






Specialty Number of Physicians
D. CIRCLE ONE:
All physicians in this partnership/group practice
have the same specialty . , . . . . . . . . . . . . . . . . I
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LARGE GROUP, THE FOLLtiING INFORMATIO~ CAN-BE OBTAINED FROM SOMEONE ELSE.)
What is the total number of full-time (35 hours or more per week) employees of your (partnership/
group) practice? Include persons regularly employed who are now on vacation, temporari& ill,
etc. Do not include other physicians. RECORD ON BOTTOM LINE OF COLW A BELON.
(1) H~—many of these full-time employees are a . . . (READ CATEGORIES BELUJ AS NECESSARY
AND RECORD NUMBER OF EACH IN COLUMN A.)
And what is the total number of part-time (less than 35 hours per week) employees of your
(partnership/group) practice? Again, include persons regularly employed who are now on vacation,
ill, etc. Do not include other physicians. RECORD ON B(YTTOMLINE OF COLW B BELOW.
(1) How many of these part-time ei,ployees are a . . . (RBADCATEGORIBS BELCWAS NECESSARY












Registered Nurse.... . . . . . . .
Licensed Ractical Nurse . . . . . . .
Nursing Aide . . . . . . . . . . . . .
physician Assistant* . . . . . . . . .
Technician . . . . . . . . . . . . . .




















physician Assistant must be ● graduate of en ●ccredited training program for Physician
Aeefetants (Fhyeician Extenders, Nedex, etc. ) or certified by the National Board of Medical
Ihcdners through the Certification EXU for Aaaiatant to the Rimary Care physician.
BEFOREYOU LEAVE,AGAIN STRESSTHAT EACH AND EYERY AMBUIAW3RYPATIENT SEEN BY THE
DOCTOR OR HIS STAFFDURING THE 7-DAYyiiiIODAm IN-SCOPEOFFICELOCATIONS (mEAT
THEM) IS TO BE INCLUDEDIN TNE SURVEY,THAT EAC~ATIENT IS TO BE RECORDEDON THE LOG,
AND ONLY THE APPROPRIATENUMBER OF PATIENTRECORDSCOMPLETED.
Thank you for your time, Dr. If you have any (more) questions,
please feel free to call me. My phone n~er is written in the folio. I’ll
call E on Monday morning of your survey week just to remind you.
11. TIME INTERVIEWENDED . . . . . . . . AM
PM
12. DATEOFINTERVIEW . . . . . . . . . . . . . . .







FOR OFFICE USE ONLY:
No. of Patients Seen: IIH 59-61/







AMERICAN HOSPITAL FORMULARY SERVICE CLASSIFICATION SYSTEM
AND THERAPEUTIC CATEGORY CODES (AHFS#)
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Copyright @1980. Drug Products Information FiIe: American Society of Hospital Pharmacists. Bethesda. Ma~land.
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Programs and Collection Procedures —F?eor, rt< i.~scr(blrg SERIES 14
the g~, neral programs of the National CerTTer r,-rr He-, l!h, S*;Jr Is-
tlcs and its nff]ces and ,~)wwons and lhe rf:,l,+ ,c,llecwn
methods usnd The}, also !nclucfc cief!ntt, ons(n(i ,,thermater,.+1
necessa~ for understanding th~ ,dala
Data Evaluation and Methods Research —St{,d,.s of r={, SERIES 15
statlsllcal methuduloqs, [rjclfidlnq e.per(me r,, ,1 te,,t,< r,f r,el.,.
SUIVEVmethods, studies of v]tal stattstlcs ,:ctllwhon r-oet hods,
new analytical techniques Oblcctlve evaluat!~os nf rellahfl,t;
of colleclerf data, and ‘contr!butrons to SIA?ISTI,::CI thyor;
SERIES 20
Analytical and Epidemiological .Studies —Re~r)rts :]resent, n~l
analytical or Interpretive studies based on wtal ~n,l health sla -
t!st!cs, carry!ng the analys!s further than thee.posllon{r~l]esof
reports tn the other series
Documents and Committee Reports, -F(rlal r,p,r?. of m:,lor
committees concerned wtlh vltr[l and h~allh >l?TI??ICS arl C SERIES 27
documents such asrecommenrfed model ,,!t.alreg, s! at, on Ia\,s
and revised birth and death certificates.
Data From the National Health Interview Survey —Sra IIst Ics
on Illness accldent,al ]n[ur]es cflsablll r’, ,,JF ,,f )7~,~pl~31
medical, dental, and other sen,lces and oth?r k$e~lth. rela, e,o
topics, all based on data coll$, cted In the cent, nwng nat!on?l
household rntervlew surve; SERIES 22
Data From the National Health E::aminatjon Survey and the
National Health and Nutrition Examination Survey .—Data
from direct exam! nation, testtng, and measurement cf nattonal
samples of the crvlllan non!nst ]t!utlonallzed po~mlat, on pro,,, de SERIES 23
the baslsfor(l ) estimates of fhs medlcallv ciefit,ed Fre.aler!ce
of spectflc diseases In the Llnlled St,ates and the dlslrliutlor,s
of the population w!th respect to ph~slc al, ph~;slolog$csl artd
psychological characteristics and 12) anaivsis of reldtlonshps
among the ~sar!o$us measurements withoul reference tc, an
expllclt flnlte tunlkmrse of persons
Data From the Institutionalized Population Surveys —EJ, s-
contlnued In 1975. Reports from these surveys are lncl,lderi ,n
Data on Health Resources: Manpower and Facilities. —
SI~II:W:s on lb,? rlLIITIberS geogrsph!c d[stnbut]on, and char-
+c!~r[st!,:s of health r~sources Includrng ph,; sw!ans, dentists,
r!,Jr; ,Ks, ,C,ther he. dth occupat!orts, hosp!tals, nurs[ng lhom~s,
and outpatient facllttles
Data From Special Surweys. -Stat !st]cs on health and health-
r+?ed +C>CIICS cdlect?d !n spec!al s!uwe~;s that arc not a Parr of
-t ms of the ]N,=!tronal Center for Healthrr, e ~cont!r, wng dala SY+ e
Starlsrlcs
Data on Mortality —I{aric,s statistics on mortaltt,f othsr than
xs mcludeti In regular annual c,r mnnthly reports. Specral
aral;ses bv cause of death age, and other demography
variables geographic and time series anal,;ses: and statlstjcs
an ,characl,zrrstw; of ~deallks not at,a!l able from the v!tal records
ha?~!C c,r, sample sur. e,:s of those records
Data cm Nata!ity, Marriage, and Diwrce. -Var[ous stat[st!cs
or! Natalie,,,,marrt age, and diuarce other than as Included !n
reg,~lar anvual or monthl~; reports. Specml analyses by demo-
graphic ,:?r!ables g,eographlc and t[me series analyses: stucf)es
SI,f fer?,l (t;, an,i s!xrIstIcs on ,ch?iracterrsf[cs of b!rths not
a~a,l.~hle fmm tt-,,s v,t,sl records based on sample sun, ew of
those recor!ds
Data From the National Monthly and Natality Surveys. —
D!sc,ont!nued n 1975 Reports from these sample surve)+s
tt~;ed @n ,;)ral recctrds are incl!uded [n Series 20 and 21,
Wspectl, .’el$;
Data From the National Survey of Family Growth.-Statls-
h!:s or! ferrl\lt&; km, ($, fc,rmat!on and d(ssolut!un, famll~;
plannlr, g arid relatwf maternal and Infant health topics derived
fr,lm a periodic s,urve; o f a nat!on,.vtde probability sample of
e~ver-m.amed women 15–W ,;ears of age.
Sertes 13
FQr a hzt of tttles ,of r~ports pfubl!shed in these series, ,.vnte to:
Data on Health Resources Utilization. —St+1lst!c< or, lhe ,AT I,- Sz, entlflc and T~chnl,:al In fwmat(on Branch
zatton of health manpower and fac[l)t!es pm.wd[ng h>ng- term ?d,~t]c,nal Center for Health Stat! st!cs
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